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Abstract 
 
 
Radiotherapy of the head and neck often results in complaints of 
xerostomia. Xerostomia is a condition characterized by a dry feeling of the 
mouth and is quite common in patients after radiotherapy of the head and 
neck. These patients often drink various liquids to alleviate these 
symptoms, but this could remove mucus from the mucosa and thus 
intensify the xerostomia. Saliva substitutes may give some relief with 
resulting improvement in their oral function and quality of life. 
 
The aim of this study is to compare the palliative efficacy of two saliva 
substitutes (Sinspeek and Xerostom®) in patients during radiotherapy for 
cancer of the head and neck. 
 
This crossover randomised controlled clinical trial was carried out on 
twenty five patients with malignant tumours of the head and neck, 
following four weeks of radiotherapy at Tygerberg Hospital. Two different 
artificial saliva substitutes (Sinspeek and Xerostom®) were tested. 
Inclusion criteria were consenting adults complaining of xerostomia. 
Exclusion criteria were patients with allergies to the test substances. 
Patients were evaluated at baseline, at the beginning of the second test 
period and after the second test period, by measuring the unstimulated 
whole salivary flow rate to determine the severity of xerostomia. Each 
patient was given both artificial saliva products and they were evaluated at 
baseline and after each test period by means of a questionnaire to report 
on the level of xerostomia. 
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Patients in the test group were between the ages of 48 and 78. In 21 of 
patients the diagnosis of the malignancy was squamous cell carcinoma. 
All patients received a cumulative radiation dose of at least 32 Gy by the 
start of the first test period. Unstimulated whole salivary flow rates were on 
average lower in the females compared to males. Unstimulated salivary 
flow rates (USFR) diagnostic of xerostomia (less than 0,2ml/min), were 
present in only eight of the patients who had subjective complaints of 
xerostomia. There were no statistically significant differences between 
sexes or age groups with relation to unstimulated salivary flow rates. 
There were no statistically significant changes in USFR collected at 
baseline, after the first test period and after the second test period. Results 
showed that the period of relief obtained from either test substance was 
not found to be statistically significant. All patients found saliva substitutes 
useful for the management of xerostomia. Sinspeek and Xerostom® were 
found to be equally useful for the management of xerostomia, with no 
statistically significant difference between them during radiotherapy. 
 
The benefit of saliva substitutes to ameliorate the effects of xerostomia is 
well established and proper advice and access to relevant preparations is 
essential. Factors such as taste and cost are important. It may be useful to 
make up samples of different saliva substitutes so that patients could 
decide which substitute they prefer. 
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Chapter One 
 
 
Introduction and Literature Review 
 
 
1.1 Introduction 
 
Xerostomia is a condition characterized by a dry feeling of the mouth and 
is fairly common in dental practice (Cassolato & Turnbull, 2003). Patients 
often drink various liquids to alleviate the symptoms, but this could remove 
mucus from the mucosa and thus worsen the xerostomia 
(Samarawickrama, 2002). 
 
Patients undergoing radiotherapy for head and neck cancer may receive 
significant doses of radiation (Regelink, et al, 1998). Radiotherapy as part 
of head and neck oncotherapy is aimed at destroying the relevant cancer 
cells. Unfortunately healthy tissue may also be destroyed in the process. 
Tissue damage of the mucosa, salivary glands and bone manifest 
clinically as mucositis, hyposalivation and osteoradionecrosis. Salivary 
glands undergo early and late changes during radiation therapy and, 
unlike the other tissues affected they do not recover. The damage results 
in both the amount and composition of saliva being affected (Regelink et 
al, 1998). 
 
Until recently saliva substitutes have not been readily available in South 
Africa. Most substances were imported and therefore the costs were 
prohibitive for patients needing to use a substitute for a long period 
(Touyz, 1988). For these reasons saliva substitutes have been developed 
and manufactured locally at affordable cost (Van der Bijl & De Waal, 
1994). 
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Visits to pharmacies by the author of this thesis made it apparent that the 
supply of saliva substitutes in South Africa has improved in recent years 
and various saliva substitutes are now readily available. The cost to 
patients varies and this may have an impact on the long-term maintenance 
for xerostomia. 
 
 
1.2 Literature Review 
 
1.2.1 The salivary glands 
 
1.2.1.1 Embryology 
 
All salivary glands are of similar embryological (ectodermal) origin. 
Epithelial buds of ectodermal origin start to develop in the sixth week of 
embryogenesis forming an epithelial groove that later transforms to an 
epithelial tunnel. This tunnel is the primitive mouth and extends into the 
surrounding mesenchyme. At the end of this blind tunnel the parotid gland 
develops by branching, budding and proliferation of the epithelium. 
Salivary gland tissues are thus of ectodermal origin, and the surrounding 
capsule and connective tissue is of mesenchymal origin. The development 
of the parotid gland is closely associated with the pharyngeal arches, 
clefts and pouches. Embryogenesis results in the formation of these 
salivary glands and the disappearance of the pharyngeal arches, clefts 
and pouches. Development of blood vessels and nerves are closely 
associated with the development of salivary glands and the facial nerve is 
associated with the parotid gland like a river delta flowing through it 
(Carlson, 2000). 
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1.2.1.2 Anatomy 
 
The macro anatomy of the salivary glands is of particular importance 
during the treatment of cancers of the head and neck. The parotids, 
submandibular and sublingual salivary glands are often in the path of 
radiation during radiotherapy of malignant tumours of the head and neck.  
Consequential tissue damage of these glands frequently results in 
xerostomia (Carlson, 2000). The micro anatomy of the various glands is 
similar. Salivary glands consist of secretory acini which form the terminal 
ends of the glands supported by myoepithelial cells. Ducts link the 
secretory components, which ultimately merge to form the major duct. The 
glands are usually surrounded by a fibrous capsule which branches inward 
to separate the gland into lobules, with loose connective tissue between 
the ducts and secretory components. The nerves, lymph and blood 
vessels also run within this connective tissue component (Cooper et al, 
1995; Van Rensburg, 1981). 
 
 
1.2.1.2.1 The major salivary glands 
 
1.2.1.2.1.1 The parotid glands 
The parotids are the largest of the salivary glands and consist of mainly 
serous acini (Sinnatamby, 1999). A few mucous cells can sometimes be 
seen in salivary glands of children (Van Rensburg, 1981). The parotid 
glands extend from the zygomatic arch to the upper part of the neck. In the 
neck area it overlaps with the posterior belly of the digastric and the 
anterior border of the sternocleidomastoid muscles (Sinnatamby, 1999). 
The anterior part of the gland overlaps the masseter muscle. The gland 
extends posterior to the mastoid process and also to below the external 
auditory meatus. The parotid gland occupies the space between the 
ramus and the mastoid and styloid processes and is close to the lateral 
wall of the oropharynx. The gland is surrounded by a fibrous capsule and 
covered with overlying skin and are both innervated by the greater 
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auricular nerve.  The parotid wraps around the posterior border of the 
ramus and also extends around the capsule of the temporomandibular 
joint. Both the parotid duct and facial nerve emerge at the anteromedial 
surface of the gland and run forward. The facial nerve runs in the parotid 
gland with all its branches anastomosing with each other forming a plexus 
(Sinnatamby, 1999). The facial nerve is most superficial with the veins 
deeper and arteries deepest in relation to each other (Carlson, 2000). The 
parotid duct is about 5 cm in length running forward over the masseter 
through the buccal fat pad and buccinator muscle and opens in the buccal 
mucosa in the region of the second upper molar. Blood supply is via 
branches from the external carotid artery and venous drainage to the 
retromandibular vein (Sinnatamby, 1999).  
 
Sympathetic nerve supply is for vasoconstriction and parasympathetic 
nerve supply is for secretory function (Carlson, 2000). Nerve supply for 
secretory motor function is from the otic ganglion running along the 
auriculotemporal nerve. Sympathetic fibres come from the superior 
cervical ganglion. Pre-gangliotic fibres come from the inferior salivary 
nucleus in the medulla, via the glossopharyngeal nerve’s branches. 
Lymphatic drainage is to parotid nodes and then to the upper group of 
deep cervical nodes (Sinnatamby, 1999). 
 
1.2.1.2.1.2 The submandibular glands 
The submandibular glands lie around the posterior part of the mylohyoid 
muscle with a smaller deep and larger superficial part connected to each 
other. These glands produce both serous and mucinous saliva and are a 
truly mixed gland.  The superficial part of the submandibular gland lies 
against the submandibular fossae laterally, the inferior part is covered by 
skin and the medial part lies against the mylohyoid muscle. The facial 
artery dents this gland in the posterior part, before it curves upward at the 
inferior border of the mandible. The deep part of the submandibular gland 
extends forward between the mylohyoid and the hyoglossus muscles, 
under the lingual and above the hypoglossal nerves. The submandibular 
duct is five centimetres in length, running forward and upwards, and opens 
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in the front of the mouth under the tongue on the sublingual papilla. Blood 
supply is from and to the facial artery and veins and lymphatic drainage is 
to the submandibular glands. Nerve supply for secretomotor fibres is from 
the submandibular ganglion which is suspended from the lingual nerve. 
Pre-ganglionic fibres come from the superior salivary nucleus in the pons 
with chorda tympani, nervus intermedius and the lingual nerve. Post-
ganglionic fibres run with the lingual nerve and secretomotor fibres 
originate from the nerve plexus surrounding the facial artery (Sinnatamby, 
1999). 
 
1.2.1.2.1.3 The sublingual glands 
The sublingual glands lie just under the oral mucosa, between the 
genioglossus and mylohyoid muscles. These two almond shaped glands 
converge and almost meet anteriorly. On the lateral borders they lie in the 
sublingual fossae. The nerve supply is from the postganglionic 
parasympathetic secretomotor fibres via the lingual nerve, which 
originates from the submandibular ganglion, in the region where chorda 
tympani preganglionic fibres synapse. The sublingual gland secretes 
mucous saliva and has over a dozen ducts of which some open directly in 
the oral cavity and others into the submandibular duct (Sinnatamby, 1999). 
 
1.2.1.2.2 The minor salivary glands 
 
The minor salivary glands are found throughout the mouth. Labial, buccal, 
palatal and lingual variants are present. These glands are mostly mixed in 
nature except for the palatal glands which are mucous in nature. The 
salivary glands of Von Ebner are associated with the circumvalate papillae 
on the posterior part of the tongue and are purely serous. The other lingual 
minor salivary glands to the anterior part of the tongue and on the dorsum 
of the tongue are mucous glands (Van Rensburg, 1981). 
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1.2.2 Saliva production 
 
Saliva production varies greatly between individuals and is influenced by 
age, sex, time of day (Epstein & Scully, 1992). The measurement of 
salivary production or flow rate is also affected by the method and site of 
collection 
. 
Adults produce over 500ml of saliva every day. This production is quite 
variable depending on demand and the physiological status of individuals. 
An unstimulated or resting whole salivary flow rate of 0,3ml/minute is 
considered to be normal, with a range of 0,29 ml/min – 0,41 ml/min 
(Sreebny, 2000), however the flow rate can be as low as 0,1ml/min during 
sleep and as high as 4,0 - 5,0ml/min during mastication or stimulation 
(Epstein & Scully, 1992; Porter et al, 2004). The average stimulated 
salivary flow rate varies between 1 - 2 ml/min (Sreebny, 2000). 
 
Saliva is produced predominantly (90%) by the major salivary glands 
(parotid, submandibular and sublingual glands). The other 10% is 
produced by the minor salivary glands. The main ingredient of saliva is 
water and the other parts are organic and inorganic factors. Saliva 
consists of two major types of secretions (serous and mucous). The 
serous component is produced predominantly by the parotid gland (75%) 
and the submandibular gland (25%) and consists of a protein rich 
secretion of proteolytic enzymes and antibodies which have a bactericidal 
function. The second component is mucous in nature and is produced 
predominantly by the submandibular, sublingual and minor salivary 
glands. Mucous saliva consists of water, glycoconjugates and mucin.  The 
main functions of this component are to prevent dehydration of the oral 
mucosa as well as aiding lubrication (Cassolato & Turnbull, 2003). 
 
Salivation is completely under nervous control. However hormones, such 
as the thyroid hormones and adrenocortical hormones have an influence 
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on the constituents of saliva. Salivation can occur due to psychological 
stimuli, such as the thought, smell and visualization of food. Several 
factors also influence the amount of salivary secretion such as the taste, 
consistency and smell of food. Mastication and different chemical stimuli 
present in food also affect salivary secretion. Additionally pregnancy, 
nausea, oesophageal irritation and trauma to the oesophagus could result 
in increased salivation (Van Rensburg, 1981). 
 
There is a relationship between sympathetic and parasympathetic nerve 
stimulation for salivation. Parasympathetic stimuli are responsible for 
vasodilatation and secretory function, but sympathetic stimuli are 
responsible for vasoconstriction which also results in salivation. 
Parasympathetic stimuli results in production of large quantities of saliva 
with a watery consistency. Sympathetic stimulation results in salivation 
with a higher organic material content with less water. The phenomenon 
that stress results in a dry mouth is not due to sympathetic stimulation of 
the salivary glands, but rather due to higher autonomic control (Van 
Rensburg, 1981). 
 
 
1.2.3 The composition of saliva 
 
Most studies evaluate whole saliva to investigate the composition of saliva 
(Tabak, 2006). The main ingredient of saliva is water, comprising over 
99% of the salivary volume (Cooper et al, 1995). The study of the 
constituents of saliva is however much more complex and it is advisable 
that glandular secretions be collected separately for the effective 
evaluation of the composition of saliva. With the advent of electrophoresis 
the perception that saliva consisted merely of a few ingredients such as 
water, salts, amylase, and mucin was proven to be incorrect. Saliva is an 
extremely complex fluid with over 40 identifiable proteins. A few of the 
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main proteins will be mentioned below (Mandel, 1989). Salivary proteins 
are identified by a procedure termed proteomics which employs Edman 
degradation to identify salivary proteins.  This recent advance has led to 
the identification of many previously undetected proteins in saliva (Tabak, 
2006). Acinar productions are genetically determined and consist of 
families of molecules which are polymorphisms of the same family of 
proteins. The proline-rich proteins are of particular interest and are the 
main parotid glycoproteins. Other proteins such as histidine rich peptides, 
cysteine, containing phosphoproteins, and tyrosine rich peptides with 
statherin as the main peptide, are also found. Amylase, a well known 
protein, has different families as well as numerous isoenzymes. 
Peroxidases have different molecular weights that are genetically 
determined. Mucin has both high- and low-molecular weight forms being 
secreted by the salivary glands. Numerous other proteins produced by the 
acinar cells include: lactoferrin, gustin, aggregating glycoproteins, 
secretory component, parotid zinc binding protein, antileukoprotease and 
epidermal growth factor (Mandel, 1989). 
 
Ductal cells produce secretory IgA, lysozyme, kallikrein, vitamin B-12, 
fibronectin and vitamin D binding proteins. The von Ebner glands of the 
tongue produce lipase. Albumin and IgG leak from the serum, through the 
gingival crevice, into the saliva (Mandel, 1989). 
  
Other ingredients include non-electrolytes such as urea and ammonia as 
well as numerous electrolytes (Mandel, 1989). 
 
All these constituents have specific functions, however it is their collective 
functioning which enhances intra-oral homeostasis (Mandel, 1989; Tabak, 
2006). 
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1.2.4 Functions of saliva 
 
It was previously thought that the most important function of saliva was its 
role in digestion. Saliva is however much more complex than previously 
conceived and it is debatable whether its digestive function is the most 
important (Mandel, 1989). Saliva consists of families of salivary molecules, 
each with multifactorial functions (Mandel, 1989; Samarawickrama, 2002).  
 
In the past the ingredients of saliva were analysed and each molecule 
identified was assigned a specific putative function. This simplistic concept 
is incorrect. Saliva is complex in nature and all the various ingredients 
work collectively to maintain oral equilibrium and health (Tabak, 2006).  
 
1.2.4.1 Lubrication 
 
Mucin, glycoproteins, proline-rich proteins, which complex with albumim, 
as well as several other molecules lubricate the oral cavity. This lubrication 
is important to facilitate chewing, bolus formation and swallowing and 
when absent, difficult and uncomfortable eating results, as well as 
retention of foods onto teeth (Mandel, 1989). Mucins bind to each other 
and form very large molecules. This process of complexing creates 
molecules which are an important factor responsible for the lubricating 
function of saliva (Samarawickrama, 2002). 
 
1.2.4.2 Mucous membrane and soft tissue integrity 
 
The mouth heals very rapidly after mucosal trauma, and it is thought that 
saliva, with the aid of epidermal growth factor, facilitates and enhances 
this process (Mandel, 1989). The viscosity of saliva also minimizes 
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chemical and mechanical damage by covering and lubricating the mucosa 
(Cassolato & Turnbull, 2003). 
 
1.2.4.3 Rinsing action 
 
The salivary flow caused by the action of muscles around the mouth and 
tongue is responsible for a washing effect of the mouth. This washing 
effect removes harmful bacteria and chemicals from the teeth and mucosa 
and is also important to eliminate debris from the mouth (Mandel, 1989). 
 
1.2.4.4 Maintenance of ecological balance 
 
Saliva is essential to the maintainance of ecological balance. The 
adherence and elimination of bacteria should be in a critical balance. 
During radiotherapy there is often a shift from less harmful bacteria, for 
example Streptococcus sangius, to the overgrowth of harmful bacteria and 
other organisms such as Candida, S mutans and Lactobacillus species. 
Saliva is important here to maintain homeostasis and to prevent the 
overgrowth of harmful pathogens (Mandel, 1989). 
 
1.2.4.5 Bacterial attachment 
 
Bacteria are dependant on colonizing surfaces for their survival (Mandel, 
1989). The mucins and amylase aids interaction between the mucosa, 
hard surfaces and certain bacteria. This is essential for bacterial 
homeostasis and survival (Samarawickrama, 2002). The mechanism by 
which saliva controls adhesion of bacteria is dependant on certain 
molecular interactions. Secretory IgA agglutinates certain bacteria which 
then cannot adhere to intra-oral surfaces. This is important as a protective 
mechanism where bacteria, which could cause caries for example are 
prevented from adhering to tooth surfaces. Mucins also compete with 
bacteria for binding space to surfaces and also agglutinate bacteria, which 
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further protect against bacterial damage. There are also other molecules, 
lysozyme and parotid basic glycoprotein, which aggregate bacteria. Other 
mechanisms such as calcium binding also inhibit bacterial adhesion 
(Mandel, 1989). 
 
1.2.4.6 Antibacterial, antifungal and antiviral activity  
 
Saliva protects the oral mucosa against infectious agents such as bacteria 
and fungi and viruses. This is facilitated by lysozyme, lactoperoxidase, 
immunoglobulin A and histatins (Cassolato & Turnbull, 2003).  
 
Lysozyme, lactoferin, salivary peroxidase as well as other salivary proteins 
and histidine-rich proteins kill bacteria, prohibit acid production and 
interfere with bacterial growth and adhesion. Lysozyme is a potent cationic 
enzyme which causes bacterial lysis by interacting with other salivary 
components and is responsible for bacterial cell membrane breakdown. It 
also reduces acid production by certain bacteria that protects against 
demineralisation and chemical damage to mucosal surfaces (Mandel, 
1989). 
 
Histidine-rich proteins also kill bacteria directly and inhibit bacterial growth 
(Mandel, 1989).  
 
Lactoferrin has bacteriostatic properties. It works by binding iron and is 
responsible for what has been termed “nutrition immunity” because of the 
competition between bacteria and lactoferrin to bind iron. Lactoferrin is 
also responsible for a bactericidal effect on Streptococcus mutans by 
binding iron (Mandel, 1989). 
 
Salivary peroxidase is a catalysing agent in the oxidizing pathway of 
bacterial glucolysis. By interference in this pathway, acid production and 
growth of bacteria are seriously affected. The antibacterial proteins in 
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saliva all interact with each other and with mucin. This interaction defends 
the oral environment against damage. There are also protective molecules 
and cells from the gingival crevicular fluid which protect against bacterial 
damage. These include serum antibodies, for example IgG, phagocytic 
cells, as well as lysozyme, lactoferrin and myeloperoxidase from the 
phagocytes themselves (Mandel, 1989). The antifungal effect of histidine-
rich peptides against damage by Candida albicans is well-known. These 
peptides are found in parotid fluids and they inhibit growth of these fungi 
(Mandel, 1989). 
 
Antiviral effects of saliva can be directly attributed to the effect of secretory 
IgA, which neutralizes viruses, in particular HIV, polioviruses and 
rhinoviruses. Mucins also have antiviral effects against the herpesvirusses 
and HIV (Mandel, 1989).  
 
1.2.4.7 pH Balance 
 
Saliva aids remineralisation of teeth by providing calcium and phosphate 
ions in a neutral pH provided by the bicarbonate phosphate buffer 
systems, thus inhibiting tooth decay (Cassolato & Turnbull, 2003; 
Samarawickrama, 2002). The pH in the mouth is almost neutral and 
bacterial and other acids are neutralized by bicarbonates, phosphates and 
histidine-rich peptides. Mastication pumps saliva into the oral cavity when 
eating, increasing the amount of saliva needed for neutralization of 
harmful acids (Mandel, 1989). 
 
1.2.4.8 Tooth maintenance 
 
Saliva has a protective function for teeth as it forms a protective pellicle 
consisting of glycoprotein (Cassolato & Turnbull, 2003; Samarawickrama, 
2002). The protective pellicle formed by salivary ingredients, consisting of 
phosphoproteins, mucin, albumin, lipids, glycolipids and phospholipids, 
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binds hydroxyapatite. This pellicle shields, lubricates and protects against 
tooth wear and prevents mineral loss from teeth. Saliva is supersaturated 
with calcium phosphate and remineralisation is regulated by staterin, 
histidine-rich peptides and cysteine-containing peptides which are 
responsible for the crystal stability and growth of calcium phosphate 
(Mandel, 1989). Proline-rich proteins further facilitate mineralisation of 
enamel (Samarawickrama, 2002). The anti-acid and buffering effects are 
also important to prevent demineralisation of the teeth (Mandel, 1989). 
 
1.2.4.9 Other functions 
 
A very important function of saliva is the preparation of a food bolus. 
Functions like speech, swallowing and chewing are also dependant on 
saliva (Cassolato & Turnbull, 2003; Samarawickrama, 2002). Saliva 
lubricates buffers, mineralises, facilitates taste, is antimicrobial and aids 
hydration (Mandel, 1989; Samarawickrama, 2002). 
 
1.2.5 Collecting saliva 
 
The accurate measurement of salivary flow rates is essential for 
experimental purposes. Salivary collections may be carried out under 
resting or stimulated circumstances. When stimulated salivary collections 
are required citric acid, paraffin wax, elastic bands, and gum base can be 
used as stimulants. Additionally pharmacological stimulants and electric 
stimulation may also be done. When unstimulated salivary collections are 
done no salivary gland stimulation should be present (Navazesh, 1993). 
 
Saliva collections could also be divided into whole saliva collection or 
collection of saliva from individual glands. When whole saliva is collected it 
consists of saliva from the major as well as the minor salivary glands. 
Saliva could also be collected from individual major glands. When saliva is 
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collected to evaluate the composition of the saliva, individual gland 
sampling is preferred. Whole saliva collection is the preferred method to 
investigate xerostomia (Navazesh, 1993). 
. 
It is important to standardize saliva collection methods because of the 
huge variation in normal salivary secretion between individuals. Factors 
such as the patient’s hydration status, time of day, body position, season 
of the year, smoking habits and the smell of food can have an effect on 
salivary production (Navazesh, 1993). 
There are different methods of collecting whole saliva samples. The 
draining method is done by letting saliva drain from the mouth over a 
specific time and at the end all saliva is expectorated into a pre-weighed 
container. The patient spits into a pre-weighed container in the spitting 
method every 60 seconds. Saliva can also be aspirated, as it forms in the 
mouth, and put in a test tube. Absorbent pre-weighed swabs can be used 
to absorb saliva and weighed again to determine the amount of saliva 
collected (Navazesh, 1993). 
 
Of all the techniques described, the spitting and draining methods provide 
the most reproducible results to quantify whole saliva. It is recommended 
that the spitting method be used when whole saliva is collected. Salivation 
could be stimulated as described earlier or samples could be collected 
without stimulation. It is also advised that a trial run be done to allow the 
patient an exercise period for up to two minutes before the actual saliva 
collection period of five minutes starts. The saliva collected during a trial 
run should be discarded and not form part of the test sample (Navazesh, 
1993). 
 
To collect salivary secretions from individual glands specialized and 
customized apparatus is needed for salivary collection. Patients often find 
these methods uncomfortable and they could also be technique sensitive 
(Navazesh, 1993). 
The subject of salivary gland function has attracted considerable attention 
in recent times. It is difficult to compare the work done by different authors 
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because standardized methods were not used for collection of salivara. It 
is therefore important to use standardized methods for saliva collection to 
make comparison of results between different studies possible (Navazesh, 
1993). 
 
 
1.2.6 Xerostomia 
 
1.2.6.1 Aetiology 
 
Causes of dry mouth can be temporary or chronic in nature.  Temporary 
xerostomia affects the resting salivary secretion only and these patients 
are not affected during mastication. Smell and taste is not affected either 
(Cassolato & Turnbull, 2003). In chronic hyposalivation resting and 
stimulated salivary flow rates are affected and these patients are 
adversely affected and mucosal and dental diseases are more prevalent 
(Cassolato & Turnbull, 2003). 
 
Xerostomia has many causes.  Common causes are systemic 
medications, high dose radiation to the head and neck and specific 
diseases such as Sjögren’s syndrome (Cassolato & Turnbull, 2003; Porter 
et al, 2004).  Chronic xerostomia can also be caused by iatrogenic factors 
such as chemotherapy and chronic graft versus host disease (Porter et al, 
2004).  Salivary gland diseases such as Sarcoidosis, HIV, Hepatitis C 
infections, Cystic fibrosis, and primary biliary cirrhosis could also cause  
symptoms of a dry mouth (Porter et al, 2004). Other causes include 
dehydration (Frost et al, 2002; Samarawickrama, 2002), and diabetes 
(Porter et al, 2004; Samarawickrama, 2002). Other rare factors 
responsible for xerostomia include amyloidosis, haemochromatosis, 
Wegener’s disease, Triple A syndrome and salivary aplastic states where 
the salivary glands did not develop (Porter et al, 2004).  
Head and neck cancer radiation therapy and Sjögren’s syndrome cause 
the severest levels of xerostomia (Cassolato & Turnbull, 2003).  
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1.2.6.1.1 Radiotherapy 
 
The main modalities for the treatment of malignancies of the head and 
neck are surgery and radiotherapy (Chambers et al, 2004).  Unfortunately 
radiotherapy damages healthy tissue as well as the cancer cells. Blood 
vessels, the mucosa, nerves, bone and salivary glands are affected 
(Chambers et al, 2004). The complications of radiotherapy could manifest 
during or after therapy. During treatment patients may suffer from 
mucositis, xerostomia, pain, infections, and neural disturbances such as 
hypersensitivity and dysgeusia (Chambers et al, 2004; Cooper et al, 
1995). Other acute complications include altered taste, redness and 
desquamation of the skin (Cooper et al, 1995). 
 
Salivary glands are easily damaged by radiation and the parotids are most 
affected (Porter et al, 2004). Radiation results in acinar atrophy as well as 
in chronic inflammation. Radiation induced apoptosis causes atrophy of 
the secretory acinar cells and this is responsible for early salivary changes 
after radiation. Radiation induced necrosis causes late changes after 
radiotherapy (Samarawickrama, 2002). A single dose of 20 Gy could 
damage salivary glands permanently and stop salivary flow (Porter et al, 
2004). Irreversible radiotherapy damage occurs at a dose of 40 Gy when 
given as separate doses of 2 Gy per day (Regelink et al, 1998). As early 
as the first week of radiotherapy salivary flow could be reduced and after a 
treatment period of five weeks salivary flow may be reduced by as much 
as 95%. Salivary glands do not recover from this damage and stimulated 
as well as unstimulated flow rates are affected (Porter et al, 2004).  
 
The treatment of squamous cell carcinoma for instance involves doses of 
between 50 and 70 Gy given at increments of 2 Gy per day. These doses 
of radiation will ultimately result in irreversible damage to the salivary 
glands (Regelink et al, 1998).   If some salivary glands are irradiated and 
some escape radiation the latter may undergo hypertrophy which to some 
extent may compensate for the symptoms of xerostomia, but after a year 
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little further improvement is seen (Porter et al, 2004).  Advances in the use 
of cone radiation techniques somewhat restrict the damage to salivary 
glands, and preservation of contralateral glands may be achieved (Porter 
et al, 2004).  
 
Radioactive iodine used in the treatment of thyroid disease can also cause 
permanent damage to salivary glands because iodine is secreted by them, 
with consequent xerostomia (Porter et al, 2004). 
 
Mucosal damage results from radiation effects on the epithelial, 
connective tissue and vascular components irradiated. The epithelium of 
both mucosal surfaces and skin has a high turnover rate in comparison to 
the vascular and connective tissue components. Tissues in a rapid cycle 
of renewal have numerous cells undergoing mitosis and are more affected 
by radiation. The epithelial basal cell layer is affected by radiation-induced 
cell death, but because the cells take up to two weeks to mature the 
clinical signs of mucositis are rarely seen earlier than two weeks after 
radiation. However both mucosa and skin are very tolerant to radiation and 
damage is typically seen with doses over 50 Gy. The oral mucosa can 
tolerate doses of about 65 Gy before it ulcerates.  
 
It is now accepted that acute and chronic radiation changes should be 
seen as a continuum and not as separate entities. Hyperaemia of 
irradiated skin results from vasodilatation and increased permeability of 
the vessels leading to oedema and the release of fibrin into the tissue. The 
fibrin undergoes fibrotic changes in the involved tissue. The vasodilatation 
has the effect of lowering perfusion of the tissues and this leads to further 
damage.  Collagen deposition due to increased fibroblast activity in the 
connective tissue was thought to be a late result of radiotherapy, but 
collagen deposition actually occurs as early as the first week after 
radiotherapy (Cooper et al, 1995). 
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Chronic complications of radiotherapy include osteoradionecrosis, soft 
tissue necrosis, rampant caries due to xerostomia and malnutrition 
(Chambers et al, 2004). There is also soft tissue ulceration, scar tissue 
formation, thinning of the mucosa, and altered taste due to damage of the 
taste buds. Fibrosis can lead to trismus and loss of elasticity of the tissues 
and even chondroradionecrosis.  
 
The management of pain due to radiotherapy complications is difficult and 
rarely effective. Topical Xylocaine rinses may be beneficial, but often 
systemic analgesics are needed. Preventative measures are important to 
limit complications and thorough follow up is needed to treat pain early 
before complications such as malnutrition develop (Cooper et al, 1995). 
 
The salivary glands are very sensitive to radiation damage and a single 
dose of over 1 Gy may lead to transient acinar damage. The serous 
components are more readily damaged and it appears that the mucinous 
components are more resistant to radiation damage. Necrotic changes 
that occur after radiotherapy  results in acinar necrosis, atrophy, ductasia, 
accumulation of inflammatory cells and fibrosis, all resulting in salivary 
gland dysfunction (Cooper et al, 1995). 
 
The management of patients who is about to have radiotherapy must 
include pre-radiation preventative treatment modalities as well as 
treatment during and after radiation therapy. Before radiation therapy 
commences any necessary extractions and routine dental treatment must 
be done. Emphasis must be placed on the provision of pre-operative 
teaching of plaque control methods, which will need to be reinforced and 
maintained throughout the life of the patient. For patients that are not able 
to achieve adequate maintenance before radiation therapy commences 
extraction of the remaining teeth is advised. During radiotherapy topical 
fluoride should be applied every second day to prevent tooth decay. 
During radiotherapy rinsing with a mixture of salt and sodium bicarbonate 
is advised to remove deposits and to dissolve thick mucous. Pain relief 
can be obtained by rinsing with a sucralfate suspension of 1 g per 15 ml of 
water. During radiotherapy there is often mucositis and yeast infections 
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and the use of a lozenge containing antifungal and antibacterial agents is 
advised from the start of, and for the duration of radiotherapy. Some 
patients will suffer from trismus. Exercising the muscles during 
radiotherapy is important to prevent trismus, because once established it 
is very difficult to treat. Patients must continue with these exercises for up 
to 6 months after therapy. It has been noticed that the occurrence of 
trismus may be initiated long after therapy was completed (Jansma et al, 
1992). Xerostomia, resulting from cancer treatment, must be managed 
effectively otherwise it may lead to a decline in the quality of life of patients 
(Chambers et al, 2004). 
 
1.2.6.1.2 Other 
 
The most common reason for xerostomia is the use of certain systemic 
drugs (Cassolato & Turnbull, 2003; Porter et al, 2004). It is outside the 
scope of this discussion to address all drugs causing xerostomia. More 
than 500 medications have been implicated (Porter et al, 2004). The 
elderly are often affected because of their higher intake of single or 
combined medication (Cassolato & Turnbull, 2003; Porter et al, 2004). 
Examples of drug groups include antidepressants, antihypertensives, 
antihistamines and antipsychotics. Patients receiving radiation for head 
and neck cancer may be using some of these medications with a 
summation of the effects of radiation and medication resulting in increased 
xerostomia (Samarawickrama, 2002; Porter et al, 2004). 
 
Often radiotherapy is combined with chemotherapy which could lead to 
more severe xerostomia (Chalmers et al, 2004) as well as additional 
complications where the actions of the chemotherapy and radiotherapy 
overlap (Cooper et al, 1995). Both radiotherapy and chemotherapy have a 
damaging effect on mucosal surfaces and patients that receive these 
therapies simultaneously have exaggerated effects of mucositis, 
ulcerations and pain. These individuals may have ulcerations that are 
more prone to infections and these patients should be monitored closely to 
prevent such infections (Cooper et al, 1995). 
 
 
 
 
 20
 
Symptoms of xerostomia are reported in up to 78% of patients receiving 
chemotherapy; their fourth most-common complaint. The number and 
dosage of different chemotherapeutic drugs used can be correlated to the 
severity of their xerostomia. Chemotherapeutic agents could change the 
consistency of saliva which further complicates xerostomia (Porter et al, 
2004).  
 
Chronic graft-versus-host disease is a common cause of xerostomia. 
Microscopically fibrosis can be seen in the parotids with resulting 
diminished salivary flow rates as well as changes in the composition of 
saliva. Both the oral epithelium and salivary epithelial cells are damaged in 
the early stages of this disease. The disease also causes damage to water 
transport, calcium ion transport and muscarinic receptors in the salivary 
glands with resulting complaints of xerostomia (Porter et al, 2004).  
 
Sjögren’s syndrome (SS) is a chronic immune modulated condition and 
has effects on exocrine glands as well as multiple other organs. The 
effects on the exocrine glands result in symptoms of dry mouth and dry 
eyes. SS can be divided into primary and secondary disease. Patients with 
primary SS have symptoms of dry eyes and dry mouth only whereas 
patients with secondary SS have additional connective tissue disease 
such as rheumatoid arthritis or systemic lupus erythematosus (Porter et al, 
2004). 
 
The salivary glands are damaged by dense infiltration of lymphocytes with 
resulting xerostomia and xerophthalmia. The diagnosis of SS depends on 
the presence of subjective complaints of dry eyes and dry mouth as well 
as objective ocular signs, microscopic signs of sialadenitis and 
autoantibodies to Ro/SSA and/or La/SSB. The diagnosis is still difficult 
because a large proportion of the population has autoantibodies to 
Ro/SSA and/or La/SSB. The aetiology of this disease is still speculative 
and factors such as viral disease have been suggested in the literature to 
be implicated in the aetiology, however this speculation has proven not to 
be a cause of the disease (Porter et al, 2004).  
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Patients with chronic sarcoidosis also have complaints of dry mouth, dry 
eyes and salivary gland enlargement. There are overlapping symptoms 
between SS and sarcoidosis, but in SS more symptoms of Raynaud’s 
phenomenon are seen and in sarcoidosis more parotid enlargement. The 
main distinguishing factors are however pulmonary symptoms and raised 
blood pressure due to raised angiotensin-converting enzyme in patients 
with sarcoidosis (Porter et al, 2004). 
 
Both children and adults with HIV disease could develop salivary gland 
disease in the presence of HIV infection. HIV salivary gland disease with 
symptoms of glandular enlargement and xerostomia, salivary gland 
enlargement due to Kaposi sarcoma, non-Hodgkin lymphoma, 
intraglandular lymphadenopathy and acute suppurative sialadenitis is 
seen. All of these entities could cause symptoms of dry mouth. Patients 
under treatment with reverse transcriptase inhibitors or protease inhibitors 
for HIV infection also often complain of xerostomia (Porter et al, 2004). 
 
Hepatitis C virus (HCV) infections often result in salivary and other extra-
hepatic diseases more frequently in comparison with other hepatic viruses. 
HCV infection causes inflammatory damage, similar but less pronounced 
than in SS, which results in xerostomia (Porter et al, 2004). 
 
Both Epstein Barr virus and human T-lymphotropic virus 1 has been 
shown to be a potential cause for symptoms of xerostomia (Porter et al, 
2004). Mumps and cytomegalovirus infections could also cause transient 
xerostomia (Cohen-Brown & Ship, 2004). 
 
Any age group can be affected, from children to the elderly. Women aged 
from 40-60 years of age, make up the largest proportion (90%) 
(Samarawickrama, 2002). It is not necessarily the age of these patients, 
but the effects of medications, salivary gland diseases, immunological 
disorders, cancer treatments as well as other systemic diseases which 
make xerostomia more prevalent in the older age group (Ship et al, 2007). 
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Patients with myelodysplastic syndromes could progressively develop 
sicca syndrome. Iron overload due to regular blood transfusions will cause 
haemosiderosis in these patients. The iron deposition in the salivary 
glands is a reason for the development of xerostomia in these individuals. 
Patients with haemochromatosis often suffer with diabetes too and the 
development of xerostomia in these patients can often be attributed to the 
diabetes (Vrielinck et al, 1988). 
 
Triple A syndrome or Allgrove syndrome is a very rare condition 
characterized by alacrima, achalasia, adrenocortical insufficiency and 
neurological abnormalities. In a report of five cases all individuals were 
found to suffer from xerostomia in addition to their other symptoms (Dumić 
et al, 2000). 
 
Conditions where the salivary glands do not develop are very rare, but 
cause symptoms of xerostomia in children and youngsters. The diagnosis 
of this condition of salivary gland agenesis is often made later when the 
patient presents with rampant caries (Hodgson et al, 2001). 
 
Patients with diabetes often complain of a dry mouth, but this could be 
attributed to the general state of dehydration of these patients or possibly 
the medications they use (Cohen-Brown & Ship, 2004; Porter et al, 2004; 
Rees, 1994).  
 
Salivary dysfunction is also reported in patients with Alzheimer’s, 
Parkinson’s disease and in patients who had strokes (Cohen-Brown & 
Ship, 2004).  
 
The following conditions have also been mentioned as causes of 
xerostomia and include: amyloidosis, primary biliary cirrhosis cystic 
fibrosis, acute sialadenitis, chronic sialadenitis, salivary stones, salivary 
tumours, cysts, and sialadenosis due to malnutrition, alcoholism and 
hyperlipidemia (Cohen-Brown & Ship, 2004).  
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1.2.6.2 The diagnosis of xerostomia 
 
The feeling of a dry mouth is very subjective. The correlation between 
objective sialometry and the subjective complaint of dry mouth is poor 
(Thomson, Chalmers, Spencer & Williams, 1998; Samarawickrama, 2002). 
Of all patients who complain of dry mouth, 35% have no objective 
evidence of xerostomia (Frost et al, 2002).  
 
When patients complain of dry mouth during the night or during daytime it 
is not indicative of xerostomia. Objective measurements of salivary 
function show that over 80% of patients who complain of xerostomia 
during the day or night do not have compromised salivary function, but 
complaints of a dry mouth during mastication are almost always a sign of 
salivary gland hypofunction. Even with masticatory and gustatory 
stimulation these patients have diminished salivation and their complaints 
of xerostomia are more often corroborated by the objective measurements 
of salivary dysfunction (Fox et al, 1987). 
 
 Clinical, radiographic and laboratory tests could be used to confirm the 
diagnosis of xerostomia. It is important to take a thorough history and do a 
detailed clinical examination. After these, specific special investigations 
could be done to aid in the diagnosis. Special tests include 
haematological, biochemical, imaging and histological investigations 
(Porter et al, 2004). 
 
The average unstimulated salivary flow rate is approximately 0,3ml/min as 
quoted by Frost et al, (2002) from a study by Edgar & O’Mullane (1996). 
Navazesh et al (1992) proposed an unstimulated whole salivary flow rate 
of not more than 0,2ml/min for a diagnosis of xerostomia. Frost et al 
(2002) suggested that an unstimulated whole salivary flow rate of 
approximately 0,15ml/min could be indicative of xerostomia. This is 50% of 
the usual flow rate (Frost et al, 2002). Ghezzi et al (2000) established in a 
study that a reduction of 45% in the normal stimulated salivary flow rate be 
referred to as hyposalivation and that this level of salivary flow reduction 
can be used as a reference level for further studies. It can therefore be 
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useful to do salivary sampling before radiotherapy commences to have a 
reference point for further comparisons. 
 
Sometimes the complaint of xerostomia is not due to lower production of 
saliva, but due to the altered consistency of saliva and this by itselfcould 
trigger a complaint of xerostomia. The quality of saliva is thus as important 
as the quantity, as this establishes the hydration and lubricating potential 
of saliva (Samarawickrama, 2002). 
 
The measurement of the level of xerostomia is difficult. Thomson et al, 
1998 reported that measuring saliva flow is an exact science due to the 
fact that different tried and tested methods exist. The quantification of 
xerostomia is subjective and patients with the same salivary flow will 
respond different to xerostomia related questions. Questionnaires were 
developed to estimate the level of xerostomia of patients as well as to 
study and compare the potential benefits of possible treatments (Thomson 
et al, 1998).  
 
 
1.2.6.3 The clinical effects of xerostomia 
 
Patients suffering from xerostomia are affected in many ways, including 
altered oral function, pain, infections and caries (Cassolato & Turnbull, 
2003; Porter et al, 2004). Other symptoms include nocturnal oral 
discomfort, speech problems (Temmel et al, 2005), difficulty in swallowing 
(Momm, et al 2005), higher rates of oral infection (Porter et al, 2004) and 
caries (Regelink et al, 1998). Patients often complain of mucosal 
soreness, burning tongue and sometimes de-papillation of the tongue 
could be observed (Porter et al, 2004). Taste can also be affected and this 
affects patients’ quality of life (Temmel et al, 2005). Individuals with 
xerostomia have viscous and foamy saliva. This type of saliva has lost its 
lubricating ability and adheres to the mucosa and teeth. Food and plaque 
adhere to the teeth and mucosa, resulting in difficulties with mastication 
and a higher incidence of mucosal infections.  
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These persons also present with periodontitis (Cassolato & Turnbull, 
2003) and acute gingivitis (Porter et al, 2004). Salivary gland enlargement 
occurs often as a result of a compensatory effect leaving the lips dry, 
cracked and sore (Porter et al, 2004). 
 
Saliva is essential in many important functions of health.  Any condition 
which affects the composition or the amount of saliva will contribute to 
diminished quality of life and will adversely affect the well being of 
patients. It is therefore imperative that xerostomia be diagnosed and 
treated early and effectively (Cassolato & Turnbull, 2003). 
 
Xerostomia will ultimately affect patient’s general well being (Momm et al, 
2005). The quality of life of such patients is affected due to interference 
with normal masticatory function as well as altered taste. They tend to 
avoid certain foods because of the difficulties encountered during 
mastication and this could lead to malnutrition. Speech problems, cracked 
lips, halitosis and problems with denture wearing are often encountered 
(Cassolato & Turnbull, 2003). 
 
Prevention, early intervention and appropriate management of 
complications are essential when treating xerostomia. 
 
 
1.2.6.4 The management of xerostomia 
 
The most important part of the management of patients with xerostomia is 
the maintenance of good plaque control to prevent further damage to the 
existing dentition. Oral hygiene instruction, modification of and correct 
plaque control methods are essential for these patients (Chambers et al, 
2004; Cohen-Brown & Ship, 2004). Caries prevention is important and 
here fluorides and dietary modification play an important role (Porter et al, 
2004). 
 
Various saliva substitutes have been tested for the protective modalities 
against enamel demineralisation. Prevention of enamel demineralisation is 
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important, since many patients with xerostomia are elderly, the importance 
of dentine protection is just as important. Elderly patients often have 
marked gingival recession and cervical erosions and sometimes root 
caries. Effective treatment of these problems and prevention of xerostomic 
complications is mandatory (Meyer-Lueckel et al, 2002). Dentate patients 
who were treated with radiotherapy often suffer with rampant caries 
typically affecting the cervical areas of teeth (Meyer-Lückel & Kielbassa, 
2006). 
 
The choice of an oral lubricant could be important to combat caries for this 
group of patients. There are several products available, some with greater 
anticaries property. Preparations such as Oralube® have a marked 
advantage for caries prevention and will be a good choice for dentate 
patients (Meyer-Lueckel et al, 2002). Biotene containing preparations and 
Glandosane® are not indicated for patients with teeth because of poorer 
defense against caries and reduced remineralisation of defects. Saliva 
Orthana, which contains mucin (Meyer-Lückel & Kielbassa, 2006) as well 
as xylitol and fluoride (Wray, 2000) protects against caries due to the 
covering effects of the mucin as well as the remineralisation effects of the 
fluoride present. Products which contain both mucin and fluoride will be 
superior in protection against dentine caries in patients after radiotherapy 
(Meyer-Lückel & Kielbassa, 2006; Wray, 2000). 
 
Xerostomic patients often complain of problems associated with the 
retention and fit of dentures. Cleanliness of dentures is also compromised.  
Candidal infections in these persons should be monitored and kept under 
control with antifungal agents (Porter et al, 2004).  
 
Topical saliva substitutes and systemic medication forms the mainstay of 
the treatment for xerostomia. Where salivary function is poor and 
symptomatic relief is needed, topical preparations are of particular 
importance (Kam et al, 2005). Most topical agents used to manage the 
symptoms of xerostomia are rapidly removed from the oral environment 
resulting in a short transient period of relief and protection (Porter et al, 
2004).  
 
 
 
 
 27
 
1.2.6.4.1 Topical agents 
The composition of natural saliva is complex with a large number of 
constituents which are responsible for the numerous functions of saliva, in 
particular, lubrication. Topical agents and artificial salivas are often used to 
alleviate the symptoms of xerostomia. These products are not as complex 
and do not resemble normal saliva. They frequently provide one main 
ingredient responsible for improved oral lubrication. These substances are 
rapidly eliminated from the oral cavity. In this regard they only provide 
short-term relief and for this reason they need to be applied very often for 
the relief of symptoms (Temmel et al, 2005). 
 
Patients treated with carboxymethylcellulose (CMC) based products found 
relief with regard to the severity of xerostomia which was marginally 
statistically significant (Temmel et al, 2005). CMC products are viscous but 
do not simulate other properties of saliva (Epstein and Stevenson-Moore, 
1992). This type of preparation did not improve the taste disturbances 
caused by xerostomia (Temmel et al, 2005). Some patients prefer this type 
of preparation compared to products containing glycerine and lemon 
(Epstein & Stevenson-Moore, 1992). There are many different CMC 
preparations available commercially which have similar beneficial effects. 
However cost and taste of these different products influence the patient’s 
preference (Vissink et al, 1983). 
 
Mucin based saliva substitutes are reportedly superior in alleviating 
symptoms of xerostomia (Davies & Singer, 1994). Saliva Orthana is one 
such preparation which is commercially available (Davies & Singer, 1994; 
Davies, 2000). In some persons Saliva Orthana causes nausea, 
diarrhoea, vomiting and intra-oral tenderness of the mucosa. Despite 
these complications, many patients persist in using this product due to the 
beneficial alleviation of xerostomia related complaints (Davies, 2000). 
Patients who were treated with radiation therapy also preferred mucin-
containing preparations because of the perceived superior protection 
capabilities to the mucosa when compared to CMC containing 
preparations (Meyer-Lückel & Kielbassa, 2006). Mucin containing 
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preparations are retained in the mouth for longer periods, smaller volumes 
are needed throughout the day and there is a noticeable improvement of 
oral function (Vissink et al, 1983). 
 
Casein phosphoprotein-calcium phosphate complex preparations such as 
Dentacal®, reportedly have similar beneficial effects as fluoride, without 
the possible negative effects of fluoride ingestion. A fluoride containing 
product may potentially cause fluoride toxicity, since patients apply 
xerostomia products very regularly and some of the product may be 
swallowed. The casein phosphoprotein-calcium phosphate preparation, 
which is a processed by-product of milk, may be swallowed without any 
adverse reactions. Patients reported favourably on this product with regard 
to taste, improvement of xerostomia related symptoms in addition to its 
preventative function against caries (Hay & Morton, 2003). 
 
The main consideration in manufacturing saliva substitutes is that it must 
have good lubrication properties. In a study by Shannon et al (2002) use 
was made of a formulation (V.A. Ora-lube) containing sodium, potassium, 
calcium, chlorine, fluoride and inorganic phosphorous. This, VA-Ora Lube 
preparation has no lubricating properties, but dentate patients had 
beneficial protective effects on their remaining teeth due to better 
remineralisation properties caused by the presence of fluoride (Shannon 
et al, 2002).  
 
Polyox contains polyethylene oxide which has viscous, wetting and elastic 
properties similar to saliva. As mentioned before these favourable 
characteristics alone do not guarantee that patients would prefer such a 
product and that factors such as taste and cost could be more important 
(Epstein & Stevenson-Moore, 1992). 
 
 
1.2.6.4.1.1 Mouthwashes 
Preparations should preferably give long lasting relief and in dentate 
individuals provide protection against caries. Patient acceptance of 
preparations is important and factors such as the lubrication potential, 
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taste, duration of relief, severity of xerostomia, type of preparation and 
cost play a role. Available preparations include Saliva Orthana (AS 
Pharma, Sweden), Salivace, Luborant (Antigen, UK), Xerostom® 
(Biocosmetics laboratory, Spain) and Oral Balance (Anglian, UK). These 
have been approved for use in xerostomia due to Sjögren’s Syndrome and 
radiotherapy (Cohen-Brown & Ship, 2004; Porter et al, 2004).  
Oralbalance Oral Lubricant (Laclede), Moi-Stir (Kingswood laboratories), 
Optimoist (Colgate Oral Pharmaceuticals) and Salivart (Xenex 
Laboratories) are well-known products, but not available in South Africa 
(Cohen-Brown & Ship, 2004). 
 
1.2.6.4.1.2 Sugar-free gum 
The chewing action when chewing gum results in increased salivary 
production. However patient compliance as well as the presence of 
sufficient functional salivary gland tissue could be limiting factors (Porter et 
al, 2004; Cohen-Brown & Ship, 2004). The stimulation of salivation by 
chewing gum is both mechanical and due to gustatory stimulation, and 
therefore flavoured gum is preferred (Davies, 2000). Products include 
Biotene dental chewing gum (Laclede) as well as other sugar free chewing 
gum (Cohen-Brown & Ship, 2004). In a comparative study of three 
different chewing gums, one placebo, one containing mucin and V6 gum, 
a commercial product, all three preparations were found to give relief to 
xerostomic patients (Aagaard et al 1992). The test substances tasted 
similar, however the xerostomia patients preferred the mucin-containing 
product. The mucin-containing product is not commercially available and 
comes at a higher price.  
 
1.2.6.4.1.3 Gels 
Some patients prefer gel preparations for the symptomatic relief of 
xerostomia (Epstein, Emerton, Le & Stevenson-Moore, 1999). Oral 
Balance® gel (Laclede Inc., Rancho Dominguez, CA, USA) has no known 
side effects and is one such product which is frequently prescribed 
(Epstein et al, 1999; Kam et al, 2005). Another example is Biotene 
moisturizing gel (Laclede) (Cohen-Brown & Ship, 2004). Oral balance gel 
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which contains hydroxypropyl methylcellulose, lactic acid, sorbitol, 
parabens and xylitol was preferred over CMC containing products by 
patients, although no statistical significant improvements in xerostiomia 
were found (Epstein et al, 1999). Xerostom® (Biocosmetics laboratory, 
Spain) is an example of a preparation available in South Africa. This 
product is eliminated from the oral cavity rapidly resulting in a shortened 
period of relief for the patient (Kam et al, 2005; Porter et al, 2004).  
 
1.2.6.4.1.4 Sprays 
Mucin spray has been found to be useful in patients after radiation therapy 
with resulting subjective and objective improvements in their xerostomia 
(Porter et al, 2004). Salivart® is an example of such a CMC based 
product, which does not contain alcohol or glycerine and gives relief to 
xerostomia related complaints (Epstein & Stevenson-Moore, 1992; ADA 
Division of Science, 2001). Xerostom® (Biocosmetics laboratory, Spain), 
Artificial saliva (Cipla Medpro, South Africa) and Dentacal (Phoscal 
holdings, Australia) are all available in South Africa. Sprays are preferred 
by some patients because they are easy to use discreetly (Epstein & 
Stevenson-Moore, 1992). 
 
1.2.6.4.2 Intraoral devices 
Saliva substitutes are swallowed and rapidly removed from the oral cavity. 
To provide an oral lubricant for longer periods of time intra-oral devices 
with reservoirs have been developed which provides a slow release of 
lubricant (Kam et al, 2005). Often xerostomia is most severe at night time, 
due to the normal nocturnal drop in salivary flow rate. Patients are usually 
restless and their sleep is disturbed by the need to lubricate their mouths. 
Patients often drink water to alleviate the dryness during these spells 
(Frost et al, 2002). Some studies have shown that intraoral lubricating 
devices are beneficial in combating this nocturnal dryness. These 
appliances differ in design for dentate and edentulous patients and are 
equipped with inbuilt reservoirs filled with artificial saliva which trickle out 
and thus allows a continuous supply of lubricant (Frost, Gardner, Price 
and Sinclair, 1997; Frost et al, 2002; McMillan et al, 2005). In the study by 
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Frost et al (2002) it was found that patients preferred such devices, 
especially at night time (Frost et al, 1997), but McMillan et al (2005) found 
that patients preferred normal lubricating methods above intraoral devices. 
A limitation to these appliances is their bulkiness which may interfere with 
speech during daytime (Frost et al, 2002). Another problem is 
accumulation of debris in these devices, if they are used when eating. It is 
advised that patients who wear dentures be provided with a separate set 
for use during mealtimes to prevent such contamination with food (Frost et 
al, 1997). Often the viscosity of substitutes used in these devices could 
cause poor compliance because the release of the lubricant cannot be 
controlled from the device. The use of gels in these devices are preferred, 
in particular Oral balance gel, and were found to be of benefit to patients 
suffering from xerostomia after radiotherapy (Kam et al, 2005). 
 
1.2.6.4.3 Others 
Substances such as evening primrose oil, available as Efamol®, has not 
shown any statistically significant benefits when compared to a control in 
xerostomia related to SS patients (Brennan, Shariff, Lockhart & Fox, 
2002). Preparations could also be available as Sugar-free sweets (Porter 
et al, 2004).  
 
Pastilles which stimulate salivary production have been proven to be 
useful for patients using oxybutynin chloride for treatment of detrusor 
instability (a neurological condition). Salivix (Provalis, UK), a preparation 
for xerostomia, allows higher doses of the oxybutynin to be tolerated 
(Porter et al, 2004). 
 
Interferon-α lozenges (150 IU of Interferon-α 3 times per day) have been 
found useful to increase both unstimulated and stimulated salivary flow in 
patients suffering from xerostomia related symptoms with no side effects 
(Porter et al, 2004). 
Toothpastes are also available for the relief of xerostomia. Biotene dry 
mouth toothpaste (Laclede) (Cohen-Brown and Ship, 2004) is an example 
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as well as Xerostom® (Biocosmetics laboratory, Spain), which is available 
in South Africa (Epstein et al, 1999).  
 
1.2.6.4.4 Systemic preparations 
 
Many different medications and substances have been researched, but 
inconsistent methods have made it difficult to compare results of these 
studies. Well-designed, randomized, controlled trials for the use of 
pilocarpine in the management of xerostomia in SS and radiotherapy 
patients have been reported.  
 
1.2.6.4.4.1 Cholinergic agonists 
Salivary production can be increased with the aid of oral muscarinic M3 
receptor agonists. Pilocarpine and Cevimeline have been in use for some 
time and both have proved to increase saliva production. Pilocarpine is 
being used in post radiation patients and more recently also in SS patients 
with promising effects (Porter et al, 2004). 
 
Pilocarpine is an acetylcholine muscarinic M3 receptor parasympathetic 
agonist and stimulates secretion by different glands. This stimulatory effect 
is not limited to salivary gland stimulation only, but also sweat glands, 
lacrimal glands and respiratory mucous glands (Porter et al, 2004). 
Pilocarpine also effects contraction of smooth muscle of the gall bladder, 
urinary tracts, biliary ducts, bronchi and the gastrointestinal tract which 
limits the prescription of this drug to severe cases. Side effects such as 
weating, nausea, headaches, gastrointestinal upsets, polyuria, increased 
lacrimation, influenza type symptoms, flushing, and palpitations are all 
unpleasant side effects. However, Pilocarpine does not have serious 
adverse reactions nor does it have serious interactions with other drugs 
(Chambers et al, 2004). It is generally well tolerated but it is advised not to 
be used in patients with asthma and other chronic obstructive pulmonary 
diseases (Porter et al, 2004). Oral pilocarpine is given at 5 mg 4 times per 
day or 10 mg 3 times per day and should be used for 8 to 12 weeks before 
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positive effects are noted (Chambers et al, 2004; Davies & Singer, 1994; 
LeVeque, et al (1993); Porter et al, 2004). 
 
Pilocarpine can also be prepared as a rinse and swallow preparation four 
times per day, 5 mg per rinse. Some patients may prefer this type of rinse 
above a conventional salivary replacement rinse (Davies & Singer, 1994).  
 
Pilocarpine increased salivary flow in post radiation patients, but the effect 
was not significant (Chambers et al 2004). Xerostomia symptoms 
improved for patients and this could be attributed to altered saliva 
secretion when pilocarpine was used (LeVeque et al, 1993). Many 
patients’ mouths are so dry that even minimal improvement in salivation 
will lead to less complaints of xerostomia (LeVeque et al, 1993). There is 
evidence in the literature that in some randomised placebo controlled 
trials, pilocarpine is of benefit for both SS and post radiotherapy treatment. 
Patients had significantly less xerostomia related complaints and oral 
soreness (Brennan et al, 2002). Pilocarpine is a preferred drug for 
treatment of radiotherapy and SS induced xerostomia. The use of this 
medication in drug-induced xerostomia is inconclusive. The oral effect of 
pilocarpine is due to increased release from glands, in particular minor 
glands which were not damaged by radiotherapy and is not responsible for 
increased activity from damaged glands (Chambers et al, 2004; Porter et 
al, 2004). 
 
Cevimeline is an analog of acetylcholine with high affinity for M3 
muscarinic receptors of salivary and lacrimal glands. Its effect on M2 
cardiac and respiratory receptors is modulated with potentially less 
adverse reactions. Conflicting evidence has been reported regarding its 
efficacy in reducing symptoms of xerostomia. Cevimeline is available as 
Evoxac® (Kahn & Johnstone, 2005), and when given at a dose of 30 mg 3 
times per day has been reported to be well tolerated with an improvement 
of xerostomia related symptoms (Chambers et al, 2004; Porter et al, 
2004). 
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1.2.6.4.4.2 Thiol-containing substances 
Research has shown that thiol-containing substances such as Amifostine® 
(WR-2721, Ethyol; Medimmune Oncology, Inc, West Conshohocken, PA) 
can be useful to limit radiation damage to salivary glands due to their 
accumulation in salivary epithelium and a scavenging effect on radiation 
induced free-radicals (Brizel et al, 2000; Kahn & Johnstone, 2005; 
McDonald et al, 1994). Side effects such as nausea, vomiting and 
hypotension have been recorded, but levels of xerostomia were found to 
be significantly less when patients received amifostine. This type of 
treatment shows great promise for future treatment and prevention of 
xerostomia for this group of patients (Brizel et al, 2000; Chambers et al, 
2004). 
 
1.2.6.4.4.3 Miscellaneous Drugs 
Bethanechol is suggested as a treatment for drug induced xerostomia. It 
is a muscarinic and nicotinic agonist and is given at 25 mg 3 times per 
day. At this dose both unstimulated and stimulated salivary flow increases 
were reported (Porter et al, 2004). Correlations between flow rate 
increases and improvement of symptoms could not be determined in post 
radiation patients, but adverse reactions such as nausea and diarrhoea 
were limited (Porter et al, 2004). 
 
Interferon-α used for the treatment of xerostomia with parenteral and 
intra-muscular preparations was found to give rise to some adverse 
reactions like nausea and vomiting etc. (Porter et al, 2004). Preparations 
at a dose of 150 IU of interferon-α resulted in no improvements for oral 
dryness or unstimulated whole saliva, but only for stimulated whole saliva 
when compared with placebo (Brennan et al, 2002). When Interferon was 
used in a lozenge preparation, alleviation of xerostomia was found without 
the adverse reactions. It is notable that although interferon is inactivated in 
the gastrointestinal tract and was not detectable in blood after the lozenge 
preparations, it still resulted in positive xerostomia related improvements 
(Porter et al, 2004). 
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Anethole trithone is another drug which is useful in increasing pilocarpine 
induced salivary production. It increases muscarinic receptor availability 
and therefore makes cholinergic stimulation by drugs such as pilocarpine 
stronger with resulting increased salivation and reduction of xerostomia 
related symptoms. Patients with radiation damage could find this drug 
useful, but its use in SS patients is not clear (Porter et al, 2004). 
 
Pyridostigmine, a cholinesterase inhibitor which has nicotinic and 
muscarinic agonistic actions is useful for patients with drug induced 
xerostomia (Porter et al, 2004). 
 
There is limited data for the use of Bromhexine for xerostomia, but it is 
suggested that benefits, with increased salivary and lacrimal flow can be 
achieved in patients with SS, with a dose of 32-48 mg per day, (Porter et 
al, 2004). In other studies there was no increase in salivation with the use 
of this preparation and only lacrimal function was improved (Brennan et al, 
2002). 
 
Trials are currently conducted to establish a potential benefit for 
Carbacholine in the treatment of xerostomia in post radiation patients 
(Porter et al, 2004). 
 
The use of Corticosteroids in the treatment of SS is not advocated until 
further studies have been conducted (Porter et al, 2004). 
 
Hydroxychloroquine given at doses of 6 – 7 mg/kg/day has produced 
variable benefits when given for a period over a year. Therefore further 
long term studies are required to test its use for the treatment of 
xerostomia in patients with SS (Porter et al, 2004). 
 
Other drugs which have been mentioned for the management of 
xerostomia includes Azathioprine, Cyclosporine, Cyclophosphamide, 
Sulfasalazine, Methotrexate and Thalidomide, but studies proving the 
benefit of their use are still inconclusive (Porter et al, 2004). 
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1.2.6.4.5 Other methods 
 
Parotid sparing radiation techniques show great promise and a variety are 
available, including shrinking field approaches, the use of lead blocks and 
masks and stents to reproduce patient position and shield peripheral 
tissue against damage. Two-dimensional radiation could also be used, 
sparing one parotid, but this technique depends on the position of the 
tumour. A new technique which makes use of three dimensional (3D) 
intensity modulated radiotherapy (IMRT) provides a higher dose to the 
tumour site, sparing other tissue from radiation damage. The contra lateral 
parotid can thus be spared with the result of less xerostomia related 
complaints and complications (Chambers et al, 2004). When patients were 
treated with IMRT there were no initial benefits with relation to xerostomia, 
but when patients were assessed 6 months later a clear benefit was found 
for this salivary gland sparing radiotherapy (RT) modality. Patients must be 
informed of the late benefit of IMR above conventional RT in the treatment 
or oral cancer (Jabbari et al, 2005).  
 
The prevention of the intensity of xerostomia is important to achieve better 
quality of life (QOL). Patients who are treated with IMRT will eventually 
have less xerostomia than patients treated with conventional radiotherapy. 
This technique is not indicated for all head and neck cancer patients, but 
where possible it will ultimately have better QOL outcomes for these 
patients (Jabbari et al, 2005). 
 
The use of electrostimulation has shown limited benefit (Brennan et al, 
2002) in patients with SS in alleviating symptoms of xerostomia and 
further testing is advisable (Porter et al, 2004). Acupuncture resulted in 
increased salivation in patients with SS and some improvement in 
symptoms was noticed, but more investigations are needed (Porter et al, 
2004). 
Dietary modification and supplements could be of benefit to patients with 
xerostomia. Vitamin supplements, cappuccino coffee, evening primrose 
 
 
 
 
 37
oil, rich fatty acids and linseed extract, for example Salinum, have been 
mentioned as aids to reduce symptoms of xerostomia (Porter et al, 2004). 
 
Salivary glands can surgically be moved to an area away from where 
radiotherapy needs to be done. Research is being done where parotid and 
submandibular tissue is transplanted to the submental area, where 
shielding techniques are used to protect this area (Kahn & Johnstone, 
2005). The transplanted tissue has shown promise to stay functional 
during and after radiotherapy, resulting in less xerostomia related 
complaints (Chambers et al, 2004; Kahn & Johnstone, 2005). 
 
With the development of gene transfer techniques in medical research, it 
might in future be possible to repair damaged salivary glands. No projects 
are currently done in this area, because it is such a new field, but the 
hypothesis shows great promise (Chambers et al, 2004). Although saliva 
substitutes alleviate the symptoms of xerostomia, Rhodus & Bereuter 
(2000) found that some patients using a saliva substitute showed 
increased whole salivary secretion rates in comparison to when a 
substitute was not used. The reason for this finding is not known, but could 
be investigated in future studies. 
 
The treatment of xerostomia for post radiation patients is symptomatic in 
nature, because the irreversible damage cannot be prevented nor 
managed with medication like pilocarpine which is used prophylactically or 
after radiation therapy (Regelink et al, 1998). More recently this notion has 
been disputed and a benefit for these drugs has been mentioned (Porter 
et al, 2004). Saliva stimulating drugs are only helpful if there is residual 
functional salivary gland tissue left after radiation therapy (McMillan et al, 
2006). Both dentate and edentulous patients have problems with speech, 
mastication, swallowing, sleeping and there is a higher prevalence of oral 
infections. In the case of denture wearers, soreness, looseness of 
dentures and denture induced ulceration of the oral mucosa are common 
complaints (Olsson & Axéll, 1991). 
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Chapter Two 
 
 
Aims, Objectives, Materials and Methods 
 
 
2.1 Aims 
 
The aim of this study is to compare the palliative efficacy of two locally 
available salivary substitutes (Sinspeek and Xerostom®) in patients during 
radiotherapy for head and neck cancer. 
 
Figure 2.1 
Sinspeek and Xerostom®  
 
 
 
 
 39
2.2 Objectives 
 
1. To measure the whole unstimulated salivary flow rates at 
baseline. 
2. To measure the whole unstimulated salivary flow rates after the 
first and second test weeks. 
3. To compare these whole unstimulated salivary flow rates at 
baseline and after the first and second test weeks. 
4. To evaluate the efficacy of both salivary substitutes by 
comparing patient’s responses using a standard questionnaire. 
5. To establish if any patient factors have an influence on the 
efficacy of the two salivary substitutes (e.g. age, gender, and 
baseline salivary flow rate). 
6. To establish whether patients found it beneficial to use a 
salivary supplement. 
7. To determine if patients would like to continue using salivary 
substitutes. 
8.       To develop a protocol for the use of salivary substitutes in the 
management of  radiotherapy induced xerostomia. 
 
 
2.3 Null hypothesis 
 
There is no statistical significant difference between the two salivary 
substitutes.  
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2.4 Materials and methods 
 
2.4.1 Study Design 
 
The study is designed as a prospective crossover randomised clinical trial.  
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Figure 2.2  
Experimental design and study population. 
 
A computer generated randomisation list was created to randomly allocate 
patients to either salivary substitute group. 
 
The patients will use both substitutes in a crossover design for a period of 
one test week for each substitute.   Each patient therefore reported on the 
efficacy of each product. Salivary substitutes are usually used ad libitum 
because they are readily eliminated from the oral cavity (Van der Bijl & De 
Waal, 1994). 
 
There was a washout period of 6 hours between the test periods of the 
two salivary substitutes.  
 
Some of the test subjects were hospitalised and others travelled to the 
hospital daily for treatment. A longer washout period was not logistically 
possible. 
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Subjects were blinded to the salivary substitutes, i.e. they were packaged 
in identical white containers marked A and B. 
  
An independent person labelled the bottles. The key which showed which 
salivary substitute was marked as A and B respectively was placed in an 
envelope and sealed for safekeeping by the independent person till after 
all data were captured.  
 
Both the patient and examiner will thus be blinded to which substance is 
used at any given time.  
 
 
 
Figure 2.3  
Pre-weighed salivary substitutes bottled in identical white plastic 
containers. 
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2.4.2 Study Sample 
 
Twenty-five patients receiving radiotherapy for cancer of the head and 
neck at Tygerberg Hospital Radiotherapy Department formed the study 
population.  
 
Mcmillan et al (2005) compared different salivary substitutes and different 
methods of application of salivary substitutes. A study population of 15 
was needed to show a 20% improvement in “the score”, with a 
significance level of 0,05, with a power of at least 90%, when a crossover 
study design was used. More subjects were used in this study to achieve 
results which will be more significant. The sample size in this study was 
calculated in consultation with a competent statistician. 
 
 
2.4.3 Inclusion and exclusion criteria  
 
2.4.3.1 Inclusion criteria 
 
1. Patients undergoing radiotherapy who have reported symptoms of 
xerostomia. 
2. Patients who have completed four weeks of radiotherapy. 
3. Patients must be consenting adults. 
4. Patients willing to sign the relevant informed consent form. 
5. Patients must be willing to provide the relevant information for 
completion of the questionnaires at the specified time intervals. 
6. Patients must be willing to provide whole saliva samples when 
required. 
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2.4.3.2 Exclusion criteria 
 
1. Patients who do not have symptoms of xerostomia. 
2. Patients who are not willing to participate. 
3. Patients who are allergic to any of the substances which are to be used 
in the study. 
4. Patients presently using a salivary substitute. 
5. Patients who are unwilling to sign the relevant consent as well as those 
not willing to provide information relevant for completion of the 
questionnaires. 
6. Patients unwilling to provide whole saliva samples when required. 
 
 
2.4.4 Identification of patients 
 
After four weeks of radiotherapy for cancer of the head and neck twenty-
five consecutive patients were selected as a convenience sample from 
patients undergoing radiotherapy for head and neck cancer according to 
the inclusion and exclusion criteria.  
 
Patients were asked to answer the following question. “Is your mouth dry?  
Are there any problems that you experience which are associated with this 
dryness?”  If the answer to this question was “yes” patients were asked to 
join the study. This question and method was also used by Momm et al 
(2004), when they identified patients for their study to compare different 
salivary substitutes.  
 
This was a subjective complaint of the patients. If there were any dropouts 
from the study, additional patients were recruited.  
 
Examples of the patient information and consent forms are included as 
appendix 1 and appendix 2 respectively. 
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The study was described to the patient and his/her role was explained in 
detail so that he/she was well informed. 
 
Patients selected to participate were asked to sign the consent form. 
 
Patients were allocated a number in sequence when entering the study. A 
computer generated randomisation list was used to assign patients to the 
two different test groups that determined who received which test 
substance first. 
 
The computer generated randomisation list is included as appendix 3. 
 
 
2.4.5 Patient examination 
 
Patients were examined by experienced consultants in the radiotherapy 
department and were referred for dental treatment before radiotherapy 
commenced. Where deemed necessary, dental clearances were advised 
to limit post radiation complications. Patients were evaluated every week 
by consultants in the radiotherapy department. This included an oral 
examination as well as a general medical examination. At this visit patient 
complications or symptoms were addressed, patients were referred for 
additional treatments and medications were prescribed as needed. 
  
 
2.4.6 Saliva collection 
 
The resting unstimulated whole saliva secretion rate was established to 
determine the severity of xerostomia. This was done at the beginning of 
the study when patients have completed four weeks of radiotherapy, at the 
beginning of the second test period when the patients would have 
completed five weeks of radiotherapy and after the second test week 
when the patients would have completed six weeks of radiotherapy. 
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Patients were asked to rinse their mouths with sterile water before saliva 
collection started. After rinsing with sterile water a rest period of five 
minutes was allowed. A one-minute period of saliva collection followed 
and was used as a practice period, and the saliva expectorated during this 
initial minute was discarded. 
 
Pre-weighed specimen bottles were then provided and patients were 
asked to expectorate saliva into the specimen bottles over a five minute 
period.  
 
The weight of the saliva expectorated was converted from gram per 
minute (g/min) to millilitre per minute (ml/min) on the basis that one gram 
weight of saliva has a volume of one millilitre. This method is similar to that 
described by Navazesh, Christensen & Brightman (1992); Navazesh 
(1993); Thomson et al (1998) when they established the unstimulated 
whole saliva secretion rate in their studies to determine criteria for salivary 
gland hypofunction. 
 
 
2.4.7 Questionnaire 
 
Patients were questioned by the principal investigator who then completed 
the questionnaire at baseline, after the first test period, and after the 
second test period. The questionnaire was developed by modifying 
questionnaires used in the WR-38 study as reported by Thomson et al 
(1998); Thomson & Williams, (2000), questionnaires used by Momm et al, 
(2005); Van der Bijl & De Waal, (1994), to allow for comparison between 
this and their studies. The completed questionnaire contained relevant 
patient information such as age, gender, type of tumour, the affected site, 
medications used, period since radiotherapy commenced and radiation 
dose. There were also specific questions relevant to the xerostomia at 
baseline and after each test period. The questionnaire is included as 
appendix 3. 
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The medication the patient took during the course of their treatment was 
also listed. Xerostomia related questions were asked at baseline, after the 
first test period and after the second test period. Patients were asked to 
rate their complaints on a four point scale with regard to dry mouth, 
difficulty in speaking, chewing, swallowing, dry mouth during sleeping, 
taste disturbances and pain or burning sensations in the mouth. 
 
Patients were asked what the effect of the salivary substitute on their 
mouth was, for how long the test substance provided relief and how they 
rated the substance in general and with regard to taste. The patients had 
to decide whether the test substance provided relief to such an extent that 
they wished to continue using it.  
This process was repeated for the first and second test periods and 
ultimately the patient had to decide which product they preferred. 
 
 
2.4.8 Test materials 
 
Two different saliva substitutes were tested. Both are available as rinses:  
 
1. Xerostom® (Biocosmetics laboratories, Madrid, Spain). The main 
ingredients of Xerostom® are: Betaine, Allantoin, Xylitol, Fluoride, 
Olive oil, Vitamin B5 and Vitamin E. It is imported by Unique Dental 
on behalf of Biocosmetics laboratories, Madrid, Spain. 
 
2. Sinspeek (Carboxymethylcellulose based saliva substitute made 
within the Department of Oral Medicine, University of Western Cape, 
South Africa) 
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Both salivary substitutes were dispensed in identical white plastic bottles 
to allow for blinding of the patients and examiner. 
 
Salivary substitutes were manufactured locally to reduce cost and 
because of the poor supply of salivary substitutes in South Africa. These 
locally manufactured substitutes contained polysaccharides such as 
carboxymethylcellulose (CMC) as well as other ingredients which were 
similar for the different recipes of artificial saliva. The additional 
ingredients, such as flavourings and artificial sweeteners, differed in 
concentration in the different recipes (Touyz, 1988; Van der Bijl & De 
Waal, 1994). 
 
The main constituents of commercial products are CMC, animal mucins 
(Van der Bijl & De Waal, 1994) or glycerine (Wiesenfeld, Stewart & Mason, 
1983), all with the addition of different electrolytes, flavouring agents and 
non-cariogenic sweeteners (Van der Bijl & De Waal, 1994). 
In some products fluoride was added to offer additional dental protection 
for dentate patients (Hatton, Levine, Margarone & Aguirre, 1987). Care 
has to be taken when a fluoride-containing supplement is used to avoid 
ingestion, as high fluoride intake levels could be harmful to the patient 
(Van der Bijl & De Waal, 1994). There is a critical fluoride concentration 
which is necessary to aid in remineralisation of tooth structure. The 
concentrations at which fluoride is present in saliva substitutes may be too 
low to aid in remineralisation and the true benefit therefore is questionable. 
It is advisable that professionals do fluoride applications as a preventative 
action against caries for dentate patients with xerostomia (Van der Bijl & 
De Waal, 1994). Fluorides in artificial salivas could have toxic effects if 
present at concentrations of over 2 mmol/l. Fluoride levels of 3 mmol/l 
shifts the balance from demineralisation to remineralisation for enamel. 
The levels for dentine will be different, and dentine is also more 
susceptible to demineralisation than enamel. Fluoride concentrations of 2 
mmol/l will also stop demineralisation of dentine when the oral 
environment is slightly acidic (Meyer-Lückel & Kielbassa, 2006).  
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Different saliva substitutes have been studied extensively and these are 
available as gels, sprays, oils or liquids (Momm et al, 2005). Patient 
preference to the taste, cost and other rheological properties influence the 
choice of a salivary substitute. This is the same for preparations containing 
CMC which is proven to reduce the symptoms of xerostomia in subjects 
with radiation induced xerostomia (Chambers et al, 2004). 
 
The main constituents are responsible for the lubrication and viscosity 
properties which are the most important properties required for a saliva 
substitute (Van der Bijl & De Waal, 1994). Wiesenfeld et al (1983) showed 
that there were no statistical significant differences in xerostomia scores 
between mucin based, CMC based or glycerine based supplements when 
used to alleviate the symptoms of xerostomia. 
 
The two salivary substitutes which will be tested in this study differ in 
composition. 
 
2.4.8.1 Sinspeek 
 
Sinspeek is made from a recipe as described by Touyz (1988); Van der 
Bijl & De Waal (1994); Wiesenfeld et al (1983) with the main constituent 
being carboxymethylcellulose (CMC) with the addition of electrolytes, 
flavourings and non-cariogenic sweeteners. This type of preparation was 
available commercially before as Glandosane®, but was removed by the 
suppliers due to financial reasons (Van der Bijl & De Waal, 1994). It was 
therefore decided to manufacture a salivary substitute similar to this 
product from ingredients readily available in South Africa, deriving the 
name from the words “sintetiese speeksel”. 
 
Low molecular weight, low-viscosity grade, CMC is preferred as a base 
(Meyerov & Touyz, 1987), but was not readily available in South Africa 
and replaced with a high molecular weight CMC of food grade (Van der 
Bijl & De Waal, 1994). The pH of Sinspeek is 6,7 which compares well with 
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some of the products available commercially for example Luborant®  
(pH=6,86) and Saliva Orthana (pH=6,69) and would give favourable 
results for remineralisation if fluoride was added. It was decided not to add 
fluoride in this preparation because patients needed alleviation of 
xerostomia by administering the substitute ad libitum, with the potential 
effect of fluoride toxicity, especially in the warm South African weather 
(Van der Bijl & De Waal, 1994). The ph of Glandosane® was much lower 
at 5,06 (Van der Bijl & De Waal, 1994) and this is why this product is not 
advisable for dentate patients because of poor remineralisation properties 
(Meyer-Lueckel et al, 2002). 
 
It was manufactured as a high viscosity salivary substitute and the main 
ingredient is a high molecular weight CMC of food grade (‘KICCOLATE’ F-
170 Nichirin chemical industries, Itami city, Japan). Other ingredients 
include KCl, NaCl, MgCl2.6H2O, CaCl2.2H2O, K2HPO4, sorbitol solution 
(70%), methyl p-hydroxybenzoate, solution of egg (1%) and oil of lemon 
(Van der Bijl & De Waal, 1994) 
 
 
Table 2.1 
The composition of Sinspeek 
 
Component Weight in (g) 
CMC 
KCl 
NaCl 
MgCl2.6H2O 
CaCl2.2H2O 
K2HPO4 
Sorbitol solution (70%) 
Methyl p-Hydroxybenzoate 
Solution of egg yellow (1%) 
Oil of lemon 
Distilled water 
9,0 
1,2 
0,84 
0,06 
0,16 
0,34 
42,80 
2,0 
2,0 
0,4 
1000 mL 
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This preparation is relatively inexpensive and is sold to patients at a 
nominal price of R20 per 200ml bottle to cover costs of manufacturing. 
 
2.4.8.2 Xerostom® 
 
Xerostom® (Biocosmetics laboratories, Madrid, Spain) is the other test 
compound and is available commercially as a mouthwash, toothpaste, 
spray and saliva substitute. For the purposes of this study design it was 
decided to use the Xerostom® mouthwash. Xerostom® contains the 
ingredients listed in the table below. 
 
 
 
 
 
Table 2.2  
The composition of Xerostom® 
 
Component Function 
Betaine 
Olive oil 
 
Fluoride 
Calcium 
Xylitol 
 
 
Vitamin E 
Allantoin 
Vitamin B5 
 
Potassium 
Citrus medica 
Lubricant 
Anti-infective, coating and anti-caries 
effects. Prolong retention in the mouth. 
Remineralisation 
Remineralisation 
Control pH, prevents plaque formation 
and retention, inhibits Streptococcus 
Mutans and stimulates salivation. 
Antioxidant, limits mucositis. 
Healing and regeneration properties. 
Healing and soothing properties, 
prevents water loss through the mucosa. 
Limits tooth sensitivity 
Stimulates salivation 
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Betaine is a human amino-acid (trimethylglycerine). It is also present as a 
natural sugar beet extract with skin lubricating (Ship, 2007) and skin 
lubricating properties (Söderling, Le Bell, Kirsolä & Tenovuo, 1998). It also 
reduces skin irritation and when combined with sodium lauryl sulfate, a 
normal ingredient of toothpastes, has been found to improve xerostomia 
related complaints (Söderling et al, 1998). Betaine has an osmoprotecting 
effect against chemical and other irritants because of its ability to bind 
humidity from air. It’s biggest use is in the cosmetics industry where it is 
used in skin, cosmetic and hair care products (Ship, 2007). 
 
Allantoin, a uric acid derivative, promotes soft tissue healing and is 
clinically proven as a treatment for numerous dermatological conditions. It 
also has soothing, non-irritating and healing properties (Lubowe & Mecca, 
1959).  
 
Xylitol is an anticariogenic sweetener, controls pH, inhibits plaque 
adherence to tooth substance, promotes remineralisation and stimulates 
salivary flow rates (Masalin, 1992). 
 
The sour taste of citrus medica is a gustatory stimulant and stimulates 
salivation (Ship, 2007). 
 
The leaves and fruit of the plant Olea europaea is a source of olive oil 
(Bisignano, Laganá, Trombetta, Arena, Nostro, Uccella, Mazzanti & Saija, 
2001). Olive oil contains long-chain aldehydes which have been proven to 
have antibacterial and antifungal effects. It therefore has the potential to 
have anti-infective properties (Bisignano et al, 2001). Plaque growth and 
adherence was inhibited by olive oil which will add to its protective effects 
against caries and gingivitis in patients suffering from xerostomia (Pretty, 
Gallagher, Martin, Edgar & Higham, 2003). The anticariogenic effect of 
olive oil might also be attributed to a covering effect of this substance. Oral 
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bacteria will also produce fewer acids, in the presence of lipids in the diet, 
in comparison with fermentable carbohydrates. These factors will result in 
an overall protective effect against caries and demineralisation. Olive oil 
also reduces attrition due to its covering and lubricating effects (Buchalla, 
Attin, Roth & Hellwig, 2003). When olive oil containing products were 
tested, significant improvements were also found in the reduction of 
halitosis (Kozlovsky, Goldberg, Natour, Rogatky-Gat, Gelernter & 
Rosenberg, 1996). 
 
Vitamin B5 stimulates healing and it was also found to have an 
antibacterial effect and it stimulated epithelial growth (Kline & Caldwell, 
1952). Vitamin B 5 also reduced water loss through the oral mucosa due 
to its hygroscopic properties as well as its barrier function (Gehring & 
Gloor, 2000). 
 
Vitamin E was found to be helpful in the management of gingivostomatitis 
and its effect was studied for the management of mucositis. Vitamin E is 
an antioxidant, reduces the recovery time of mucositis and has anti-ageing 
properties (Wadleigh, Redman, Graham, Krasnow, Anderson & Cohen, 
1992).  
 
Fluoride is proven to have anticariogenic effects owing to its remineralising 
effects on decalcified enamel and dentine (Stookey, DePaola, 
Featherstone, Fejerskov, Möller, Rotberg, Stephen & Wefel, 1993). 
 
Xerostom® is available to patients at a cost of R115 per 250ml bottle. 
 
As far as could be established this was the first study, comparing the 
efficacy of locally available salivary substitutes, in South Africa. 
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2.4.9 Test period 
 
The two different artificial saliva substitutes were tested in a prospective 
crossover randomised controlled trial.  
 
The test substances Xerostom® and Sinspeek were presented in the same 
packaging to allow for blinding of the test subjects and marked as 
substance A or B respectively by an independent person.  
 
Patients were provided with verbal instructions on the use of the salivary 
substitutes according to the manufacturers. Patients received 250ml 
artificial saliva for ad libitum use for a one-week period.  
 
Patients were provided with a register, which had to be completed every 
time they used the salivary substitute, of which a copy is enclosed as 
appendix 4. 
  
Data from this register was captured on the questionnaire and provided 
the information on how many times per day they used the salivary 
substitute. 
 
An independent person allocated the patients to the relevant test group by 
means of the randomisation list to determine which test substance they 
will receive first. An independent person dispensed the relevant test 
substance and gave instructions to the patient on its usage.  
 
The randomisation list was designed by utilizing Microsoft Excel® software 
with the help of an independent statistician.  
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An independent person indicated which substance was used first by using 
the code A or B on the questionnaire.  
 
Patients were evaluated at baseline (Visit 1) and after each test period 
(Visit 2 and Visit 3) by means of the questionnaire to report on their level 
of xerostomia.  
 
The test compound was used for one week by every patient. After using 
the first substance for one week an independent person collected the 
remaining test substance from the patients on the morning of the seventh 
test day (Visit 2) and the amount of artificial saliva used was calculated.  
 
A washout period of six hours was allowed. 
 
An independent person dispensed the next test substance, again giving 
the relevant instructions on its usage.  
 
The independent person noted the second test substance on the 
questionnaire as A or B.  
 
Patients again completed the register to determine how many times the 
artificial saliva was used per day.  
 
At the end of the second test period (Visit 3) the amount of artificial saliva 
used was determined and captured. 
 
The researcher was thus blinded to what substance the patient received at 
any time. 
 
All questionnaires were filled in by the author. The information provided in 
the questionnaires was captured on a spreadsheet to provide the data for 
statistical interpretation.  
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Only after capturing the data was it possible for the author to establish in 
which sequence substances were tested for the different individuals.  
 
2.4.10 Data Analysis 
 
The data obtained from the questionnaires was entered in an Excel® 
spreadsheet. A statistician was consulted to analyse the data by utilising 
SPSS® software. Most of the measurements were nominal or ordinal in 
nature. Rates and proportions were calculated by utilizing the SPSS® 
software. The Chi-squared test was used to decide whether differences 
were statistically significant. In cases of ordinal measurements the 
Wilcoxon signed rank test was used to draw the relevant conclusions. 
Other applicable non-parametric techniques were used to investigate the 
patients’ experience of the two different products. The results from this 
study will be compared to other appropriate literature.  
 
 
2.4.11 Ethical Considerations 
 
Approval for the study was obtained from the Research Ethics Committee 
of the University of the Western Cape. Informed consent was obtained 
from all participants after explaining the possible advantages, aim and 
procedures that were to be used.  
 
Patient confidentiality was strictly enforced and patients were able to exit 
the study at any time for any reason without prejudice.  
 
The test substances have been used extensively with no adverse 
reactions reported. Results will not be available for examination by any 
supplier prior to publication.  
 
The author declares that he had no financial interest in any of the products 
used or tested in this study. 
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Chapter Three 
 
Results 
 
In Table 3.1 below the joint and marginal frequencies with respect to 
Gender and Treatment Order are noted. Furthermore, descriptive statistics 
such as the Mean Age, Standard Deviation, Minimum and Maximum are 
given in each respective cell four joint cells (AB, Male); (AB Female); (BA 
Male); (BA Female) and two marginal cells (AB Total); (BA Total). 
 
Table 3.1 
Descriptive Statistics with relation to the Age of 25 patients participating in 
the evaluation of two different salivary substitutes 
 
    Gender   
Treatment order Data Female Male Total 
AB Number of subjects 6 7 13 
  Average Age 62 56. 59. 
  Standard Deviation  8.89 10.84 10.01 
  Minimum 49 47 47 
  Maximum 71 75 75 
BA Number of subjects 3 9 12 
  Average of Age 58 59 59 
  Standard Deviation  16.77 10.45 11.44 
  Minimum  48 46 46 
  Maximum  78 76 78 
 
 
From table 3.1 it is apparent that the Average Age of the experimental 
group was 59. The average age of the males were 3 years older than the 
average age of the females. The patients in the two treatment groups (AB 
and BA) had similar Mean Ages. More Males were included in the study. 
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Table 3.2 
Demographic data: Frequency Distribution of Tumour sites and Histology 
 
Tumor sites Frequencies   Tumour Histology Frequencies
Mouth 11  Squamous Cell Carcinoma 21 
Larynx 6  Adenocarcinoma 1 
Hypopharynx 3  Acinic cell adenocarcinoma 1 
Oropharynx 2  Lymphoepithelioma 1 
Salivary Glands 2  Schwannoma 1 
Maxillary Sinus 1     
 
 
From Table 3.2 above it is apparent that the majority of patients had 
cancer of the Oral Cavity, followed by the Larynx, Hypopharynx, 
Oropharynx, Salivary glands and the Maxillary sinus. The most common 
histological diagnosis was that of Squamous Cell Carcinoma though some 
rare tumours are also listed in the above table. 
 
 
Table 3.3 
Descriptive Statistics of the Radiation Dose for the complete group of 25 
patients participating in the evaluation of two different salivary substitutes 
 
Average Radiation Dose  36 Gy 
Standard Deviation   3.35 Gy 
Minimum  32 Gy 
Maximum  44 Gy 
 
 
From Table 3.3 above it is apparent that all the Radiation Doses ranged 
between 32 to 44 Gy and with a mean of 36 Gy. The Minimum Radiation 
Dose reported was 32 Gy and the Maximum Radiation Dose was 44 Gy. 
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Table 3.4 
Descriptive Statistics of Salivary Flow Rates in ml/min 
 
Gender Data Baseline
End of 
First 
Week 
End of 
Second 
Week 
Female Number of Unstimulated Saliva 9 9 9 
  Average of Unstimulated Saliva 0.29 0.35 0.27 
  Standard Deviation of Unstim. Saliva 0.25 0.27 0.20 
  Minimum of Unstim. Saliva 0.00 0.02 0.02 
  Maximum of Unstim. Saliva 0.80 0.65 0.61 
Male Number of Unstimulated Saliva  16 16 16 
  Average of Unstimulated Saliva 0.54 0.54 0.59 
  Standard Deviation of Unstim. Saliva 0.41 0.35 0.41 
  Minimum of Unstim. Saliva 0.08 0.08 0.06 
  Maximum of Unstim. Saliva 1.33 1.09 1.66 
 
 
From the data presented in Table 3.4 it is apparent that the Females’ 
Average Unstimulated Salivary Flow Rates were consistently lower than 
that of the Males. The differences between the Baseline Unstimulated 
Salivary Flow Rates, Unstimulated Salivary Flow Rates after the First Test 
Week and Unstimulated Salivary Flow Rates after the Second Test Week 
did not vary significantly in either the Male or Female groups. The 
complaint of subjective xerostomia was reported by all the test subjects, 
but the objective measurements of the Average Unstimulated Salivary 
Flow Rates were consistently higher than 0,2ml/min in both Males and 
Females. 
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Table 3.5 
Descriptive Statistics of the Average of the three Unstimulated Saliva 
collections with respect to Treatment Order and Gender in ml/min 
 
    Gender   
Treatment 
order 
Data Female Male Total 
AB Number of saliva collections 6 7 13 
  Average of Unstim. saliva collection 0.26 0.46 0.36 
  Standard Deviation  0.17 0.31 0.27 
  Minimum 0.03 0.09 0.03 
  Maximum  0.45 0.89 0.89 
BA Number of saliva collections 3 9 12 
  Average of Unstim. saliva collection 0.39 0.64 0.58 
  Standard Deviation  0.31 0.37 0.36 
  Minimum 0.04 0.10 0.04 
  Maximum  0.59 1.30 1.30 
Number of collections 9 16 25 
Average of Unstimulated saliva collection Average 0.30 0.56 0.47 
Standard Deviation 0.22 0.35 0.33 
Minimum   0.03 0.09 0.03 
Maximum   0.59 1.30 1.30 
 
 
From table 3.5 above it was apparent that a clear tendency existed for a 
lower unstimulated salivary flow rate for the Females in comparison to the 
Males. This tendency was found regardless of which treatment sequence, 
(AB) or (BA), was followed. 
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Figure 3.1 
Scatter Plot of Average Unstimulated Salivary Flow versus Age for 
Females 
 
 
From figure 3.1 above it was apparent that the age of the females did not 
play a role in the subjective reporting of xerostomia by the test subjects. 
Only four Females had objective measurements of xerostomia with a 
tendency towards the older age group. This tendency was not statistically 
significant. 
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Figure 3.2 
Scatter Plot of Average Unstimulated Salivary Flow versus Age for Males 
 
 
Males reported subjective xerostomia related complaints more often than 
the Females. The Average Unstimulated Salivary Rate was not related to 
age for the Male patients. Only four Male patients had objective 
measurements of Average Unstimulated Salivary Flow rates consistent 
with a diagnosis of xerostomia and the distribution of these patients was 
not related to their age. 
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Figure 3.3 
Average of three saliva collections (ml/per minute) versus the Range of 
these measurements 
 
 
From the empirical distribution of the Average of the saliva collections it 
was clear that approximately 30% of these Averages were equal to or less 
than 0.2 ml/min, illustrating that the majority of patients participating in this 
study had a saliva flow rate of more than 0.2 ml/min. From figure 3.3 
above it was clear that the Range of the three measurements increased 
directly proportional as the Average increased.  With respect to variability 
(distributional properties) it was of importance that the Range was larger 
than all of the corresponding Averages of the three collections. 
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Figure 3.4 
Salivary Flow Rate over Treatment AB Sequence 
 
 
Figure 3.4 above depicted the salivary flow rates for baseline, after the first 
test period and after the second test period for the AB test group. It is 
apparent that the Unstimulated Salivary Flow Rates of none of the patients 
changed significantly over the course of the test period. Individual patients 
(25) and (12) showed major deterioration and improvements respectively, 
with regard to objective measurements of Unstimulated Salivary Flow 
Rates, but this was not of statistical significance. 
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Figure 3.5 
Salivary Flow Rate over Treatment BA Sequence 
 
 
Figure 3.5 above depicted the Salivary Flow Rates at baseline, after the 
First and after the Second Test Period, for the BA test group. It was again 
apparent that the Unstimulated Salivary Flow Rates in none of the patients 
changed significantly over the course of the test period. Only one patient 
(22) showed a major improvement with regard to the objective 
measurement of Unstimulated Salivary Flow Rate, but this was not 
statistically significant. For the rest there were no statistically significant 
changes in Unstimulated Salivary Flow Rates over the duration of the test 
period.  
 
From figures 3.4 and 3.5 above it was evident that only nine patients had 
Unstimulated Salivary Flow Rates of 0,2 ml/min or less at baseline; eight 
had Unstimulated Salivary Flow rates of 0,2 ml/min or less after the first 
treatment period and eight had Unstimulated Salivary Flow Rates of 0,2 
ml/min or less after the second test period.
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Table 3.6 
Descriptive Statistics of the Range (Maximum minus Minimum) of the 
three saliva collections from 25 participants (ml/min) 
 
Average of Range of three collections    0.61 
Standard Deviation  0.40 
Minimum Range 0.06 
Maximum Range 1.66 
 
Table 3.6 indicates that there were some patients with a low variability 
(Range) but even in these cases the corresponding Range was more than 
the Average.   
 
 
Table 3.7 
Descriptive Statistics of the Duration of Relief measured in Minutes 
experienced by the patients using artificial saliva A or B respectively 
during the First Week of the crossover study. 
 
    
Gender 
  
Treatment order  Data Female Male Total 
AB 
Number of subjects with relief  6 7 13 
 (While using A) Average of duration of relief 25.83 23.57 24.62 
 Median 27.50 20.00 — 
  Standard Deviation 11.58 18.87 15.34 
  Minimum 15 0 0 
  Maximum 45 60 60 
BA 
Number of subjects with relief 3 9 12 
 (While using B) Average of duration of relief 20.00 32.56 29.42 
 Median 30.00 27.50 — 
  Standard Deviation 34.64 25.05 26.59 
  Minimum 0 3 0 
  Maximum 6 80 80 
 
 
From the raw data it was evident that the participants in this study 
estimated the duration of Relief in rounded numbers for example five 
minutes, ten minutes, and so on. This again was a subjective estimation of 
the time they had relief from symptoms of a dry mouth.  
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In Table 3.7, in two of the four cells (both belonging to Males), the 
distribution of the Period of Relief was skewed towards the longer periods, 
comparing the Averages and Medians within each of the four cells.   
 
For the females in two of the four cells the distribution of the Periods of 
Relief was skewed toward the shorter periods of relief, when comparing 
the Averages and Medians within the four cells.  
 
A non-parametric test (Wilcoxon Signed Rank) was used to investigate 
whether the two Medians of Relief differs (the one reflecting the Relief 
from Product A and the other from Product B) of Relief differs.  The paired 
differences were not statistically significant (p>0.05). 
 
Table 3.8 
Descriptive Statistics of the Duration of Relief measured in Minutes 
experienced by the patients using artificial saliva A or B respectively 
during the Second Week of the crossover study  
 
    
Gender 
  
Treatment order  Data Female Male Total 
AB 
 Number of patients with relief  6 7 13 
  (While using A) Average of duration of relief 23.83 25.00 24.46 
 Median 20.00 20.00 — 
  Standard Deviation 23.46 17.56 19.59 
  Minimum 3.00 10.00 3.00 
  Maximum 70.00 60.00 70.00 
BA 
Number of patients with relief 3 9 12 
  (While using B) Average of duration of relief 15.00 43.33 36.25 
 Median 15.00 20.00 — 
  Standard Deviation 5.00 30.52 29.09 
  Minimum 10.00 5.00 5.00 
  Maximum 20.00 80.00 80.00 
 
As can be seen from table 3.8 above, the distribution of the period of relief 
is skewed towards the longer periods in all four cells (Median less or equal 
to the Averages), indicating that some subjects made more liberal 
estimates. The result of the Wilcoxon Signed Rank Test confirmed that 
there was no difference between the reliefs reported between the test 
subjects. 
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Table 3.9a 
The joint Frequency Distribution of the Dry Mouth complaint prior to the 
First Treatment Period and After the First Treatment Period (Treatment 
order AB)    
 
Treatment order  
AB 
    
      
Count  
Complaints - Dry Mouth_Post 1st Treatment  
Complaints - Dry 
Mouth_Pre Any 
1_None 2_Minor 3_Moderate 4_Severe Total 
1_None      
2_Minor 1  2  3 
3_Moderate  2 3  5 
4_Severe  2 1 2 5 
Total 1 4 6 2 13 
 
 
For the AB group, in Table 3.9a, the diagonal cells were indicated by 
means of yellow and their condition did not change with respect to the 
First Treatment Period (5 patients). The presence of subjects above the 
diagonal indicate that their subjective estimations of dry mouth 
deteriorated during the First Treatment Period (2 patients), and the 
condition improved for those individuals counted below the diagonal of the 
frequency table (6 patients). The improvement of the 13 patients using 
Product A (first) was not statistically significant. 
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Table 3.9b 
The joint Frequency Distribution of the Dry Mouth complaint prior to the 
First Treatment Period and After the First Treatment Period (Treatment 
order BA)  
 
Treatment order  BA     
      
Count  Complaints - Dry Mouth_Post 1st Treatment 
Complaints - Dry 
Mouth_PreAny 
1_None 2_Minor 3_Moderate 4_Severe Total 
1_None      
2_Minor  2 2  4 
3_Moderate  1 4 1 6 
4_Severe   2  2 
Total  3 8 1 12 
 
 
For the BA group, the condition of six patients did not change over the 
Second Period with relation to Dry Mouth, three deteriorated and three 
improved. Clearly the improvement showed no statistical significant 
difference.  
 
 
Table 3.9c 
The joint Frequency Distribution of the Dry Mouth complaint After finishing  
the First Treatment Period and After completing the Second Treatment 
Period (Treatment order AB)  
 
Treatment order  AB     
      
Count  Complaints - Dry mouth_Post 2nd Treatment  
Complaints - Dry 
Mouth_Post 1stT 
1_None 2_Minor 3_Moderate 4_Severe Total 
1_None  1   1 
2_Minor 1 2 1  4 
3_Moderate 1 2 3  6 
4_Severe  1  1 2 
Total 2 6 4 1 13 
 
 
The condition of six patients did not change over the Second Period with 
relation to Dry Mouth, two deteriorated and five improved. There was no 
statistical significance in this finding. 
 
 
 
 
 69
 
Table 3.9d 
The joint Frequency Distribution of the Dry Mouth complaint After finishing 
the First Treatment Period and After completing the Second Treatment 
Period (Treatment order BA)  
 
Treatment order  BA     
      
Count  Complaints - Dry mouth_Post 2ndtTreatment  
Complaints - Dry 
Mouth_Post 1stT 
1_None 2_Minor 3_Moderate 4_Severe Total 
1_None      
2_Minor 1 1 1  3 
3_Moderate  4 4  8 
4_Severe  1   1 
Total 1 6 5  12 
 
 
The condition of five patients did not change over the Second Period with 
relation to Dry Mouth, one deteriorated and six improved. Again no 
statistical significance was found in this finding. 
 
 
Table 3.10a 
Pearson Correlation Matrix of the AB Group of seven measurements 
including two derived measurements, Unstimulated Salivary Collection 
Average (from three collections) as well as the Range thereof 
 
AB Unstimul 
Salivary 
Coll. A 
Unstimul 
Salivary 
Coll. B 
Unstimul 
Salivary 
Coll. C 
Unstimul 
S. Coll. 
Average
Range 
A to C 
Relief 
First 
Week 
Relief 
Second 
Week
Unstimul Salivary Coll. A 1       
Unstimul Salivary Coll. B  0.3410 1      
Unstimul Salivary Coll. C  0.5156 0.7099 1     
Unstimul S. Coll. Average 0.7875 0.8026 0.8822 1    
Range A to C 0.7405 0.8606 0.8230 0.9780 1   
Relief First Week -0.5313 -0.0859 0.0971 -0.2439 -0.2443 1  
Relief Second Week 0.1171 0.3654 0.1448 0.2470 0.3041 -0.4071 1 
 
 
It was noteworthy that if the patient produced a considerable salivary flow 
before the start of the study it was likely that he or she had less Relief at 
the end of the First Week. When patients had advanced salivary 
hypofunction with poor unstimulated salivation before the start of the first 
treatment it was likely that they experienced more Relief at the end of the 
 
 
 
 
 70
First Week (only significant at the 10% level). For the treatment order AB 
the implication of the negative correlation between the Relief of the First 
and Second Treatment was that if the patient received a long Relief in the 
First Week the Relief of the Second Treatment Period was shorter, and 
when patients had short Relief in the First Week they experienced longer 
Relief in the Second Week. 
 
 
Table 3.10b 
Pearson Correlation Matrix of the BA Group of seven measurements 
including two derived measurements, Unstimulated Salivary Collection 
Average (from three collections) as well as the Range thereof 
 
BA Unstimul 
Salivary 
Coll. A)
Unstimul 
Salivary 
Coll. B)
Unstimul 
Salivary 
Coll. C)
Unstimul 
S. Coll. 
Average
Range A 
to C 
Relief 
First 
Week 
Relief 
Second 
Week 
Unstimul Salivary Coll. A 1       
Unstimul Salivary Coll. B  0.8980 1      
Unstimul Salivary Coll. C  0.8493 0.8431 1     
Unstimul S. Coll. Average 0.9562 0.9541 0.9490 1    
Range A to C 0.9272 0.8861 0.9678 0.9757 1   
Relief First Week 0.1260 -0.2301 -0.0675 -0.0614 0.0312 1  
Relief Second Week -0.2287 -0.2993 -0.4184 -0.3384 -0.3715 0.4066 1 
 
 
In the AB Group it is worthwhile to observe that the correlation between 
the Relief experienced from the First Treatment was negatively related to 
the Relief experienced from the following Second Treatment (Pearson 
Correlation = -0.4071; Spearman Rank Correlation = -0.4231), compared 
to the corresponding positive correlation for the BA Group (Pearson 
Correlation = 0.4066; Spearman Rank Correlation = 0.4688).  For the BA 
Group the relationship between the Relief obtained from the respective 
products was positive, in comparison with the AB Group, which was 
negative.  The Relief obtained from B offered positive predictability for 
Relief from A.  When changing the order of usage to AB the expected 
Relief from B could not be positively predicted (in fact, it was negative).   
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Table 3.11 
Four tables combining Treatment Order as well as the Final Preference of 
the participants; the subjective choice after using the relevant test 
substance is shown within each of the two-by-two sub-tables 
 
 
Treatment order AB     Treatment order AB   
Gender (All)     Gender (All)   
Prefer Prod at end A     Prefer Prod at end B   
          
Count of Name Go on using B     Count of Name Go on using B   
Go on using sub A No Yes Total   Go on using sub A No Yes Total 
No 0 0 0   No 0 3 3 
Yes 5 2 7   Yes 0 3 3 
Total 5 2 7   Total 0 6 6 
          
          
Treatment order BA     Treatment order  BA   
Gender (All)     Gender (All)   
Prefer Prod at end A     Prefer Prod at end B   
          
Count of Name Go on using A     Count of Name Go on using A   
Go on using sub B No Yes Total   Go on using sub B No Yes Total 
No 0 6 6   No 0 0 0 
Yes 0 3 3   Yes 1 2 3 
Total 0 9 9   Total 1 2 3 
 
 
 
The discussion of the four sub-tables will be performed by concentrating 
on the top two tables where the treatments order was AB (summing the 
table totals resulted in 13 subjects).  It was found that of the 13 subjects 
using the AB sequence seven preferred Product A after both test periods 
and six (in the right-hand table) preferred Product B at the end of both 
periods.  All seven of these subjects would continue with Product A and of 
the other six (in the right-hand table); only three would prefer to continue 
with Product A.   
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The information (opinions) contained in the second row of two-by-two 
tables would now be discussed. The treatment order was BA (summing of 
the table totals resulted in 12 subjects). Of the 12 subjects using the BA 
sequence, nine preferred to use product B after the first treatment period, 
but after the second treatment period three of these patients had a 
preference for product A. This could be due to the fact that it was a while 
since they experienced the characteristics of product B. The preference for 
the respective products was not of statistically significant importance. 
 
 
Table 3.12a 
Frequency table of Preferences of subjects after experiencing both 
products (Treatment order AB) 
 
 
Treatment order  AB   
    
Count  Gender   
Prefer Product Female Male Total 
A 3 4 7 
B 3 3 6 
Total 6 7 13 
 
 
For the AB Group seven patients preferred Product A and the remainder 
of the 13 in this group preferred Product B.  It is necessary to keep in mind 
that they have stopped using Product A at least seven days before they 
expressed their preference.  It was possible that they could not clearly 
remember the effect of Product A at that stage.  For this particular group 
there was no clear-cut preference for Product A or B. 
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Table 3.12b 
Frequency table of Preferences of subjects after experiencing both 
products (Treatment order BA) 
 
Treatment order  BA   
    
Count  Gender   
Prefer Product Female Male Total 
A 3 6 9 
B 0 3 3 
Total 3 9 12 
 
 
Nine patients in the BA Group preferred Product A and the remainder 
(three) of the 12 in this group preferred Product B. It is necessary to keep 
in mind that they have stopped using Product B at least seven days before 
they expressed their preference. It was possible that they could not clearly 
remember the effect of Product B at that stage.  Under the assumption 
(null hypothesis) of equal preferences for the two products the probability 
of such an outcome (nine for A and three for B) was 0.146 (two-sided). 
This could result in patients reporting on their desired preference when the 
BA sequence was used in either way (B) or (A) and was not of statistical 
significance. 
 
Not one of the test substances A or B was found to be statistically 
significantly superior in comparison to the other. 
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Chapter Four 
 
Discussion and Conclusions 
 
4.1 Discussion of results 
 
During the data collection period three individuals exercised their right to 
withdraw from the study. All of these individuals provided whole 
unstimulated saliva samples at baseline, questionnaires were completed 
and patients were provided with their first test substance. At the second 
visit all three individuals withdrew from the study. They had not used any 
of the substitutes. One patient withdrew because she was not prepared to 
complete a log of when the test substance was used. Another patient said 
she was confused with the whole process and was not prepared to 
participate. The third patient was worried that the test substance would 
aggravate his radiation induced mucositis and was not prepared to risk 
using our test substance to alleviate his xerostomia. Patients who 
withdrew from the study were replaced by individuals that fulfilled the 
inclusion and exclusion criteria and were prepared to participate in the 
study according to methodology of this study. Radiotherapy was provided 
with three different radiotherapy units. During our study period 
maintenance work was carried out on one machine and another machine 
was shut down to carry out essential repairs. Therefore only 25 patients 
who satisfied the inclusion and exclusion criteria, and who were prepared 
to participate in the study, could be recruited in the data collection period. 
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The average age of the test group approached 60 years of age. The 
youngest patient was 48 and the oldest patient 78 years of age. The males 
in our test population were on average three years older than the females, 
but this was not statistically significant. In this study population the females 
showed a tendency to develop cancer earlier than the males, although this 
was not statistically significant. 
 
The mouth was the most common tumour site with 11 patients affected. 
The larynx was the second most common affected area with six patients 
affected followed by the hypopharynx affected in three patients, 
oropharynx in two patients and the maxillary sinus in one patient. Of the 
25 patients, 21 were diagnosed histologically with squamous cell 
carcinomas. There were also single subjects with adenocarcinoma, acinic 
cell adenocarcinoma, lymphoepithelioma and a schwannoma. 
 
The participants in our test group have all completed a radiation treatment 
program of four weeks in the Tygerberg Radiotherapy Department. 
Patients receive a daily dose of 2 Gy and by the time they have completed 
a four week course of radiotherapy they would have received a cumulative 
dose of at least 32 Gy. The average radiation dose received in this group 
was 36,35 Gy with a maximum of 44,26 Gy and a minimum of 32 Gy. 
Radiation doses of this magnitude are responsible for irreversible salivary 
hypofunction and the stimulated as well as unstimulated salivary flow rates 
are affected (Porter et al, 2004; Regelink et al, 1998)  
 
Not all patients approached to join the study had subjective xerostomia 
related symptoms and so they were not included in our study group. All 
the patients in our test group had radiotherapy related complications by 
the end of the fourth week of radiotherapy which included pain, mucositis, 
loss of taste, xerostomia, oral discomfort and they felt generally unwell. 
Patients received palliative medications to limit pain and discomfort. 
Where fungal and bacterial infections were diagnosed, they were 
managed appropriately.  
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Most of the measurements used to evaluate the responses to the artificial 
saliva were subjective to a more or lesser extent. It was interesting to note 
that the females in our study population had average unstimulated salivary 
collections which were lower than those found in the males. The average 
unstimulated salivary collections were still at a level higher than that 
accepted for an objective diagnosis of xerostomia. It is accepted that the 
unstimulated salivary flow rate should be no more than 0,2 ml/min for such 
a diagnosis (Navazesh et al, 1992). It also showed that the males had 
subjective complaints of xerostomia with even higher unstimulated salivary 
secretions. In the test group about 70% of patients did not have objective 
unstimulated salivary flow rates diagnostic of xerostomia. 70% of patients 
had unstimulated salivary flow rates of greater than 0,2 ml/min. This 
proportion of patients without concrete measurements implicating 
xerostomia was much higher than reported by Frost et al, (2000) where 
35% of patients were reported to have no objective evidence of 
xerostomia. Females had consistently lower average unstimulated salivary 
flow rates than males in our test population regardless of which test 
substance they used first, (A) or (B). Nine females were included in our 
study group and of these only four had objective unstimulated salivary flow 
rates of less than 0,2 ml/min. On average these females were of older 
age, but this was not statistically significant. Of the 16 males only four had 
objective unstimulated salivary flow rates of less than 0,2 ml/min. Males 
tended to complain of xerostomia in the presence of higher unstimulated 
salivary flow rates compared to the females, but this was not statistically 
significant. It might have been worthwhile to have taken unstimulated 
salivary collections of patients before they commenced radiation therapy. 
This would have been useful to determine whether patient’s salivation 
decreased from the radiation. Frost et al (2002) & Ghezzi et al (2000) 
suggested that an unstimulated whole salivary flow rate of 50% of the 
usual flow rate could be used to make an objective diagnosis of 
xerostomia rather than a measurement of the differences between 
individuals. 
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During the collection of samples it was often possible to identify those 
patients who produced significant amounts of saliva although they 
complained of xerostomia related symptoms. The consistency of this 
saliva was often very watery and sometimes very viscous. This suggested 
that it is not always the amount, but often the consistency and composition 
of saliva which gives rise to subjective complaints of xerostomia (Thomson 
et al, 1998; Samarawickrama, 2002).  
 
There were no significant differences between unstimulated salivary 
collections taken at baseline, after the first test period and after the second 
test period. It was expected that further radiation therapy during the first 
and second treatment periods would further reduce salivation, but this was 
not the case. It was also hypothesized that the use of a salivary substitute 
might increase unstimulated salivary secretions as seen in a study by 
McMillan et al (2006), but this was not seen in our study population. 
 
The subjective complaints of xerostomia were evaluated by asking 
questions with relation to “dry mouth”, “difficulty speaking”, “difficulty 
chewing”, “difficulty swallowing”, “dry mouth when sleeping”, “taste 
disturbance” and “pain or burning sensation”. Al of these were graded by 
the patients according to severity “none”, “minor”, “moderate” and 
“severe”. From the statistical evaluation it was found that the only 
xerostomia related question which showed some relevance was that of 
“dry mouth”.  
 
After data capturing, the code to which was test substance (A) and which 
test substance (B), held by our independent person, was revealed. 
Substance A was identified as Sinspeek and substance B was Xerostom®. 
 
In the test population using the AB sequence, six patients experienced 
improvements for “dry mouth” over the first week, five reported no changes 
and in two patients the dry sensation increased. In this AB group, five 
patients improved, six remained the same and two deteriorated during the 
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second test period. There was no statistical significance in these findings 
with regard to which test substance gave superior relief for “dry mouth”. 
 
For the BA sequence group there were three patients with improvements, 
six with no change and three deteriorated with regard to “dry mouth” 
during the first test week. During the second test week, for this group, six 
patients showed improvements, five with no change and one deteriorated 
with regard to “dry mouth”. Again there was no statistically significant 
difference between the two products for the relief of “dry mouth”. 
 
Patients also reported on the duration of relief from the salivary 
substitutes, in a subjective manner. Time intervals reported by the 
subjects ranged in compartments of five and ten minutes. There were two 
males who reported prolonged time of relief, completely outside the range 
reported by other patients. Neither test substance was found to be 
superior to the other with relation to the time of relief obtained. There was 
not statistically significant proof that any of the test substances was 
superior to the other with regard to “relief”. 
 
When patients had unstimulated whole salivary flow rates above that 
accepted for a diagnosis of xerostomia, there was less relief from the test 
substances. Those subjects who had salivary gland hypofunction clearly 
reported more “relief” from their xerostomia when using a salivary 
substitute. Patients in the AB group had more relief from Sinspeek when 
they had salivary gland hypofunction, but only at a significance level of 
10%. Subjects in the AB group also reported poor relief from Xerostom® 
after they had long periods of relief from Sinspeek during the first week. 
Patients in his group who reported short relief from Sinspeek in the first 
week had a tendency to report longer relief from Xerostom® in the second 
test week. Relief in the first treatment period was thus negatively 
correlated to that of the second treatment period.  
 
In the BA group the correlation was found to be positive, so patients who 
experienced relief from the test substance in the first period could be 
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positively predicted to have relief from the second test substance too. Both 
the Pearson Correlation Test and the Spearman Rank Correlation Test 
confirmed these tendencies. 
 
When patients indicated that they would like to continue using a specific 
test compound, the sequence in which the substances were used played a 
role. This might be owing to the fact that by the time they had used the 
second test substance, they had forgotten the effect of the first substance. 
This could have influenced their favoring of the last test substance.  
 
All the patients in this study group suffered from other radiation induced 
oral complications, the most common being mucositis and pain. Some 
patients with mucositis reported that Xerostom® caused a burning 
sensation, which influenced them to use this product less. This finding was 
not significant. Similarly some patients disliked Sinspeek because it made 
their saliva more viscous and they also disliked the consistency and taste. 
Again there was no statistical significance. Sixteen patients preferred 
Sinspeek and this was the preferred saliva substitute at the end of both 
test periods; but there was no statistical significance in the manner in 
which patients reported their preferences. All patients reported that they 
would like to carry on using a salivary substitute to relieve xerostomia-
related complaints. 
 
The Null Hypothesis was proven to be correct for this study. It was 
concluded that both test products were found to be equally useful in the 
management of xerostomia, with no statistically significant difference 
between Sinspeek and Xerostom®. 
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4.2 Conclusions 
 
Correct management strategies for patients with cancer of the head and 
neck are helpful in limiting oral disease and discomfort. Management 
therefore be before, during and after radiotherapy to limit the 
complications of radiation induced xerostomia (Meyerov & Touyz, 1987).  
 
Every individual should be able to enjoy everyday life, to do everyday 
tasks, and to interact with other people. When persons manage to do this, 
they are in a state of well-being and is referred to as “quality of life”.  
 
Perceptions of quality of life (QOL) vary between individuals and the 
evaluation of this should be based on these individual perceptions 
(Epstein, Robertson, Emerton, Phillips and Stevenson-Moore, 2001). 
Cancer alone will affect the QOL of patients, and treatment of head and 
neck cancer has numerous adverse effects so that QOL will certainly be 
affected in different ways for each individual. The older the patient the 
more their QOL is affected and the QOL in patients, who suffered from 
therapy related complications like pain, dysphagia and speech 
impediments occurring after radiotherapy of the head and neck will 
adversely affect QOL. In certain patients the complaints of post treatment 
pain will not subside for as long as 6 months after radiation. Mucosal 
sensitivity and dysphagia will affect the food patients prefer and could lead 
to malnutrition and loss of the enjoyment of eating. Xerostomia was a 
complaint of 95% of patients of whom almost three quarters complained of 
severe xerostomia (Epstein et al, 2001). 
 
The longer a patient survives after cancer the more satisfied with life he or 
she becomes. 
 
Products alleviating the symptoms of xerostomia are an important part in 
the management of these patients. The range of products available in 
South Africa has improved in recent years. Prescribing of medicaments for 
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pathological conditions would seem to be a simple matter, but this is often 
not the case where QOL is important and patients have financial 
limitations. Almost all salivary substitutes are classified as toiletries and 
some as food substitutes. For these reasons health care funders are 
reluctant to cover the cost of these preparations (Price, 2003).  
 
The benefit of salivary substitutes to ameliorate the effects of xerostomia 
is well established and proper advice and access to relevant preparations 
is essential. There are variations in preference for certain substances 
between individuals. It could help to use samples of different salivary 
substitutes so that patients could decide which substitute they prefer. 
Favorable characteristics which improve xerostomia alone will not 
guarantee that patients will prefer such a product and factors such as taste 
and cost could be more important (Epstein & Stevenson-Moore, 1992). 
 
It is encouraging to see that some pharmaceutical companies are now 
importing different salivary substitutes into South Africa, which will lead to 
a bigger range of products from which the patients could choose. 
 
4.3 Future extensions 
 
Potential future extensions of this project would be to test some of the 
other salivary substitutes locally available, as well as to compare the 
efficacy of different types of preparations like gels, toothpastes or sprays.   
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4.4 Limitations 
 
In a study by Momm et al (2005) a period of four weeks after radiotherapy 
was allowed for the early and late effects of the radiotherapy to manifest. 
Patients undergoing radiotherapy are generally unwell and it might be 
advantageous to consider postponing testing for some longer period after 
radiotherapy to allow for general healing of radiation induced 
complications, before testing saliva substitutes. 
 
Owing to social and economic factors relevant to this study group it was 
not possible to expect patients to return at regular intervals merely to 
complete a questionnaire. Many of the participants of this study were 
illiterate and supervision was necessary with the filling in of 
questionnaires. These were the main reasons why a healing period was 
not allowed after radiation treatment, because they would not be under 
treatment for a period which would coincide with the study period.  
 
During the planning of this study it was calculated that more than 15 
patients were needed to make the conclusions statistically meaningful 
than the study by Momm et al (2005). On the advice of an independent 
statistician it was decided to use a study population of 30 patients. When 
the results were evaluated it became clear that owing to the subjective 
nature of the reporting on levels of xerostomia in fact it would be 
necessary to use an even larger study population to arrive at statistically 
significant conclusions. The test group of only 25 subjects is thus an 
acknowledged shortcoming of the study. 
 
Only preparations available as rinses were used here to make it possible 
to design the study as a double blind retrospective study. It was not 
feasible to include all saliva substitutes available in South Africa in this 
study. 
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4.5 Appendix 1: 
Patient information document 
 
Title of project: A comparison of two salivary substitutes in the 
management of xerostomia during radiotherapy for cancer of the head and 
neck.  
Reference number: 06/9/16 
 
Principal investigator:  Dr Johann Lochner  
 
Address:  Department of Oral medicine and Periodontology 
Faculty of Dentistry 
  University of the Western Cape 
Private Bag XI  
  Tygerberg 7505 
Aim: 
The aim of this study is to compare the palliative efficacy of two locally 
available salivary substitutes in patients during radiotherapy for head and 
neck cancer. 
 
Procedures: 
Patients who complain of a dry mouth will be asked to join the study. Dr 
Lochner will fill in a questionnaire after questioning patients. All patients 
will receive a dental examination and be referred for dental treatment if 
necessary. A test will be done to establish how dry the patient’s mouth is 
by collecting saliva expectorated into a bottle after four and five weeks of 
radiotherapy. Patients will receive two saliva substitutes for a week each 
and after each test week questions will be asked again and the 
questionnaire completed by Dr Lochner. After both saliva substitutes are 
tested the questionnaire will be finalized. 
 
Possible advantages: 
Patients receiving radiotherapy often complain of a dry mouth. They 
usually drink fluids to alleviate the symptoms of the dry mouth. Some 
patients could benefit from using a saliva substitute for the symptoms of a 
dry mouth. 
 
The substances used as saliva substitutes have all been tested before and 
are safe to use. Very few adverse reactions have been reported. 
 
After completion of the study, patients will receive advice about the 
different substitutes used and where they could purchase them. 
 
There would be no costs involved for the patients who participate in this 
study. There will not be any remuneration for patients participating in the 
study nor will they be given free saliva substitutes after completion of the 
study. 
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4.6 Appendix 2: 
Informed consent document 
 
Title of research project:  
A comparison of two salivary substitutes in the management of 
xerostomia during radiotherapy for cancer of the head and neck. 
 
Reference number: 06/9/16  
 
Principal investigator:  Dr Johann Lochner 
 
Address:  Department of Oral Medicine and Periodontology 
Faculty of Dentistry 
  University of the Western Cape 
Private Bag XI 
  Tygerberg 7505 
 
DECLARATION BY OR ON BEHALF OF THE PATIENT/PARTICIPANT 
 
I, the undersigned, ……………………………, ID number,………………., 
the patient/participant or in my capacity as …………..of the 
patient/participant, ID number…………………….., of 
……………………………………………..….(address), 
 
A. CONFIRM THE FOLLOWING: 
1. I, the patient/participant, was invited to take part in abovementioned 
research project which took place at: The Tygerberg Hospital 
2. The following aspects were explained to me, the patient/participant: 
2.1 Aim 
2.2 Procedures 
2.3 Alternatives 
2.4 Risks 
Materials: No known risks. 
Routine sterile protocols will be followed. 
Possible advantages: Symptoms of xerostomia are likely to be 
improved. 
2.5 Confidentiality 
The identity of the patient/participant will not be disclosed nor 
will the identity be disclosed in any future publication.  
2.6 Access to results 
The patient/participant will have access to the results, once 
these have been analysed and published, by contacting the 
researchers. 
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2.7 Voluntary participation/refusal/termination 
Participation in the project is voluntarily.  The patient/participant 
or his/her representative can refuse participation or can 
terminate participation at any stage of the study.  The 
termination of participation will have no detrimental effect on any 
further or future treatment of the patient/participant at this 
institution.  The researcher can also terminate the participation 
of the patient/participant if this seems to be in the best interest 
of the patient/participant. 
3. The information was supplied and explained by Dr Lochner in 
English/Afrikaans and I confirm that I understand the 
English/Afrikaans language. If I did not understand the explanation 
by Dr Lochner in these languages, an interpreter was engaged to 
translate the explanation in the language of my preference. 
4. I was not forced to consent to participate and I understand that I 
can terminate participation at any time without any penalization 
whatsoever. 
5. Participation to the project will have no additional costs for me, the 
patient/participant. 
 
B. AGREE VOLUNTARILY TO PARTICIPATE IN THE 
ABOVEMENTIONED PROJECT/ALLOW THE PATIENT TO 
PARTICIPATE IN THE ABOVEMENTIONED PROJECT. GIVE MY 
CONSENT THAT INFORMATION GATHERED FROM THIS STUDY 
BE USED FOR FUTURE STUDIES AND PUBLICATIONS. 
 
Signed/consent at The Tygerberg Hospital on…………………….2007. 
 
 
 
Signature or right thumb print of patient Signature of      
witness 
or representative of patient/participant 
 
 
 
DECLARATION BY RESEARCHER 
 
I, Johann Georg Lochner, declare that  
 
• I explained the content of this document to 
……………………………..or her/his representative; 
• I encouraged the patient/participant to ask questions and that 
enough time was allowed to ask questions; 
• I communicated in the English language and that no translator/a 
translator was used. 
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Signed at the Tygerberg Hospital ………………2007. 
 
 
……………………………….   …………………………… 
Signature of researcher   Signature of witness 
 
 
DECLARATION BY TRANSLATOR 
 
I, …………………………….., confirm that I 
• translated the content of this document from English to 
………………………for the patient/participant or his/her 
representative; 
• explained the content of this document to the patient/participant or 
his/her representative; 
• translated the questions asked by the patient/participant or his/her 
representative as well as the answers provided by the researchers; 
• gave a factual correct interpretation of all communicated 
information. 
 
Signed at the Tygerberg Hospital ……………… 2007. 
 
 
………………………………….. 
 ……………………………….. 
Signature translator    Signature witness 
 
 
 
 
 
 
IMPORTANT MESSAGE TO THE PATIENT/PARTICIPANT OR 
HIS/HER REPRESENTATIVE 
 
Dear patient/representative of the patient 
 
Thank you for your participation to this project.  If you request any 
further information regarding this project or if any 
discomfort/emergency should arise as a result of this project you can 
contact me, Dr J G Lochner, at the following numbers: 
021 9373168 during office hours 
0724197792 outside office hours 
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4.7 Appendix 3: 
Randomisation list 
 
Subject# 
Start 
treatment 
Second 
treatment
1 B A 
2 A B 
3 B A 
4 A B 
5 A B 
6 B A 
7 A B 
8 B A 
9 B A 
10 A B 
11 B A 
12 A B 
13 B A 
14 A B 
15 B A 
16 A B 
17 A B 
18 B A 
19 A B 
20 B A 
21 A B 
22 B A 
23 B A 
24 A B 
25 A B 
26 B A 
27 A B 
28 B A 
29 B A 
30 A B 
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4.8 Appendix 4: 
Questionnaire  
 
 Salivary substitute study         
                   
1. Patient information            
                   
 Patient no:                     
 Name:                             
 Address:                             
                                
                         
 Tel no:               
File 
no:             
                   
 Gender:   Male 
 
Female             
                   
 Age:      
Today's 
date                 
         d d m m y y     
 Commencement of radiation (date)                 
  Radiation dose (Gy) received to date               
                   
2. Medication                           
                   
                   
3. Tumour Site (Tick appropriate box)          
                   
  Oropharynx    Hypopharynx  Mouth  Larynx  Nose      
                   
  Salivary glands    Thyroid  Cervical lymphatic nodes      
                   
    Unknown primary                     
                   
                   
4. Histology               
                   
   Squamous cell carcinoma    Adeno-carcinoma 
 
Lymphoma    
                   
 Other                            
                   
                   
5. Do you use anything for your dry mouth    Yes    No     
                   
                   
6. If 'yes' what do you use?                     
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7. Xerostomia related questions at baseline (Tick appropriate box)     
                     
 Complaints                  
 Dry mouth       None  Minor   Moderate  Severe     
 Difficulty speaking     None  Minor   Moderate  Severe     
 Difficulty chewing     None  Minor   Moderate  Severe     
 Difficulty swallowing     None  Minor   Moderate  Severe     
 Dry mouth when sleeping    None  Minor   Moderate  Severe     
 Taste disturbance     None  Minor   Moderate  Severe     
 Pain or burning sensation    None  Minor   Moderate  Severe     
                     
 Unstimulated saliva collection            g      
                     
                     
8. Product used in first treatment period   Product A   Product B    
 Amount dispensed       g           
           d d m m y y     
 Commencement of saliva treatment (date)                 
                     
 Complaints after first treatment period           
 Dry mouth       None  Minor   Moderate  Severe     
 Difficulty speaking     None  Minor   Moderate  Severe     
 Difficulty chewing     None  Minor   Moderate  Severe     
 Difficulty swallowing     None  Minor   Moderate  Severe     
 Dry mouth when sleeping    None  Minor   Moderate  Severe     
 Taste disturbance     None  Minor   Moderate  Severe     
 Pain or burning sensation    None  Minor   Moderate  Severe     
                     
 Unstimulated salivary collection           g       
                     
 Additional questions after first treatment period       
                     
 
What was the effect of the saliva substitute on your 
mouth?          
           None  Minor   Moderate 
 
Favourable
 How long does the relief stay after an application?       Minutes    
  
Amount of artificial saliva 
returned         g     
                     
 How do you rate the tested compound?            
 (i) 
In 
general        Very Bad   Bad  Acceptable   Pleasant 
 (ii) 
In 
taste         Very Bad   Bad  Acceptable   Pleasant 
 Would you like to go on using the test            
 substance?         Yes   No        
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9. Product used in second treatment period   Product A   Product B 
 Amount dispensed       g           
                     
           d d m m y y     
 Commencement of saliva treatment (date)                 
                     
                     
 Complaints after second treatment period          
 Dry mouth       None  Minor   Moderate 
 
Severe     
 Difficulty speaking     None  Minor   Moderate 
 
Severe     
 Difficulty chewing     None  Minor   Moderate 
 
Severe     
 Difficulty swallowing     None  Minor   Moderate 
 
Severe     
 Dry mouth when sleeping    None  Minor   Moderate 
 
Severe     
 Taste disturbance     None  Minor   Moderate 
 
Severe     
 Pain or burning sensation    None  Minor   Moderate 
 
Severe     
                     
 Unstimulated saliva collection            g      
                     
 
 Additional questions after second treatment period     
                     
 
What was the effect of the saliva substitute on your 
mouth?          
             None   Minor   Moderate 
 
Favourable
 How long does the relief stay after an application?       Minutes    
  Amount of artificial saliva returned         g     
                     
 How do you rate the tested compound?            
 (i) 
In 
general        Very Bad   Bad  Acceptable   Pleasant 
 (ii) 
In 
taste         Very Bad   Bad  Acceptable   Pleasant 
                     
 Would you like to go on using the test            
 substance?         Yes   No        
                     
                     
10. Question after both substances were tested        
                     
 Which compound would you prefer to use?           
                     
   Product A Product B           
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4.9 Appendix 5: 
Patient Log 
 
Patient Name  &  Surname                        
                  
Patient No                   
Product used during the First Week    Product A   Product B     
                  
Product used during the Second Week   Product A   Product B     
                  
Day One            A tick for each occasion of usage    
                  
Morning (Before Twelve O'Clock) Afternoon (After Twelve O'Clock) Evening (After Six) 
                  
                                  
                  
Day Two            A tick for each occasion of usage    
                  
Morning (Before Twelve O'Clock) Afternoon (After Twelve O'Clock) Evening (After Six) 
                  
                                  
Day Three            A tick for each occasion of usage    
                  
Morning (Before Twelve O'Clock) Afternoon (After Twelve O'Clock) Evening (After Six) 
                  
                                  
                  
Day Four            A tick for each occasion of usage    
                  
Morning (Before Twelve O'Clock) Afternoon (After Twelve O'Clock) Evening (After Six) 
                  
                                  
                  
Day Five            A tick for each occasion of usage    
                  
Morning (Before Twelve O'Clock) Afternoon (After Twelve O'Clock) Evening (After Six) 
                  
                                  
                  
Day Six            A tick for each occasion of usage    
                  
Morning (Before Twelve O'Clock) Afternoon (After Twelve O'Clock) Evening (After Six) 
                  
                                  
                  
Day Seven            A tick for each occasion of usage    
                  
Morning (Before Twelve O'Clock) Afternoon (After Twelve O'Clock) Evening (After Six) 
 
 
 
 
 
